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Specific ligand targeting has been shown to facilitate drug transport across biological 
membranes. The aim of this PhD was to investigate whether ion-pairing a drug (theophylline) 
with a polyamine transporter system (PTS) substrate (polyamine) could actively target drug 
delivery into the lungs from the pulmonary circulation. To try and achieve this, cyclodextrins 
were used in a co-solvent to engineer a physically stable cyclodextrin-ion-pair complex. FT-
IR and HPLC binding assays showed that theophylline (THE) bound most tightly to spermine 
(SP) (THE-SP: pKFT-IR = 1.96 ± 0.04, pKHPLC = 2.81 ± 0.06) than to spermidine (SPD) (THE-
SPD: pKFT-IR = 1.93 ± 0.05, pKHPLC = 2.79 ± 0.065) followed by ethylenediamine (EDA) 
(THE-EDA: pKFT-IR = 1.43 ± 0.02, pKHPLC = 2.49 ± 0.05) and the least with ethylamine (EA) 
(THE-EA: pKFT-IR = 1.32 ± 0.04, pKHPLC = 2.43 ± 0.042). Ion-pairing theophylline with the 
counter-ions significantly increased the drug’s solubility and reduced its lipophilicity. The 
formation of 1:1 cyclodextrin/[theophylline-spermine] ion-pair complexes were confirmed by 
NMR. Reducing the dielectric constant of the vehicle was found to increase the binding 
affinity of theophylline to spermine (pKTHE-SP in 70 % PG: pKTHE-SP = 2.11 + 0.045 > pKTHE-
SP in 10% EtOH: 2.05 + 0.053 > pKTHE-SP in water: 1.96 + 0.06) when assayed with FT-IR. 
However, it was found that the ion-pair, regardless of the vehicle used or when complexed 
with cyclodextrins, dissociated rapidly when the pH of the solution was dropped to 7.4. The 
theophylline-spermine uptake in A549 showed that the PTS was involved in the membrane 
transport of the drug. In addition, a sustained delivery of theophylline was achieved when 
cyclodextrin was complexed with the ion-pair, which suggested cyclodextrins could stabilize 
the ion-pair association. Hence, a cyclodextrin-theophylline-spermine complex described 
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1.0 General introduction 
 
The development of a new active pharmaceutical ingredient (API) is very expensive 
(estimated in excess cost of USD 1 billion) and time-consuming (Hughes et al. 2011; 
Fortunak et al. 2014). This can be seen in the case of acetaminophen or better known as 
paracetamol which is currently the most widely used drug worldwide for its painkilling 
properties. Paracetamol was first discovered in late 1800’s but was only available 
commercially in the market in the mid of 1950’s (Brune et al. 2015). Considering this fact, 
scientists often resort to reformulating the “old” drugs using different strategies with the aim 
to optimize their therapeutic efficacy. However, the main obstacle remains on how to deliver 
the active therapeutic agents effectively to the target sites with minimal or no side-effects. 
Drug delivery using traditional administration approaches is often characterized by non-
specific biodistribution, poor selectivity and limited effectiveness (Khan et al. 2017; Kumar 
et al. 2017; Z. Wang et al. 2017).  
 
A targeted drug delivery system could overcome some of the current limitations of drug 
development (Liu et al. 2017; Khan et al. 2017; Z. Wang et al. 2017). It can enhance drug 
efficacy by increasing drug accumulation at the target site which can reduce effects of off-
target tissues and minimizes undesirable side-effects and improve patient compliance (Mu et 
al. 2018). This concept is not new, but rather it is a continuation of the “magic bullet” 
concept proposed by Paul Ehrlich, a German researcher back in 1906 (Bosch & Rosich 
2008). After more than 100 years, the quest for a “magic bullet” continues to be a challenge 
to scientists around the world. In principle, the challenge lies on (i) identifying the proper 
target to tackle a particular state of disease, (ii) employing an effective active therapeutic 
agent to treat the disease and (iii) designing an efficient means to carry the active agent to the 
  3 
site of interest. Passive drug targeting relies on the affinity of the drug to the endothelial cell 
lining whilst an active targeting is achieved through a ligand-targeted approach, i.e., attaching 
the drug to a specific carrier (Wang et al. 2017; Szczepanowicz et al. 2016).  
 
If a drug carrier is used for targeted delivery, the carrier must be recognized by the target cell 
for cellular internalization and deposition of the drug to occur (Kim & Cochran 2017). In 
addition, an ideal carrier must be non-toxic, biocompatible and chemically stable in-vivo. It 
should also be biodegradable and easily excreted from the body (Liu et al. 2017). Over the 
last few decades, various materials including macromolecules, liposomes, dendrimers and 
most recently nanomaterials have been synthesized with the aim of drug targeting (Banerjee 
et al. 2017). Unfortunately, very few effective site-specific drug systems are currently used in 
the clinic. The subsequent sections of this chapter will focus on targeted drug delivery to the 
lung and the strategies which have been tested to-date. It will discuss the potential use of ion-
pairing to generate targeting complexes that are labile and have the potential to deliver and 
dissociate from the drug to release it in a specific tissue. At the end of this chapter, the future 
work that is needed to evaluate ion-pair strategy is outlined and from this the aim of this PhD 
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1.1 Targeting drug to the lungs 
 
The major challenge for lung diseases treatment such as asthma and chronic obstructive 
pulmonary disease (COPD) is the limited ability of the conventional drug delivery systems to 
delivery drugs effectively to the target site which results in low therapeutic effect. To 
improve this, lung-targeted drug delivery (LTDT) could be employed to provide an efficient 
means to deliver therapeutic agents to the lung whilst minimizing drug distribution in off-
target sites. The pulmonary system, because of its unique physiology, offers an attractive 
target site for the delivery bioactive compounds. This system comprises of the airways, lungs 
and muscles, which together facilitate the process of gaseous exchange in the body (Figure 
1.1). In humans, the airways can be divided into the respiratory zone, which covers the 
airways and the alveoli, and the conducting zone that is made up of trachea, bronchi and 
bronchioles (Banerjee et al. 2017).  
 
20 2 The Human Respiratory System
Fig. 2.1 Schematic of the respiratory system displayed by the upper and lower respiratory tract
region
place. Anatomically, the respiratory system can be divided into the upper and lower
respiratory tract. The upper respiratory tract includes the organs located outside of the
chest cavity (thorax) area (i.e. nose, pharynx, larynx), whereas the lower respiratory
tract includes the organs located almost entirely within it (i.e. trachea, bronchi,
bronchiole, alveolar duct, alveoli). In the next section, the individual respiratory
organs are discussed.
2.2 Nose and Nasal Cavity
2.2.1 Anatomy of the Nose and Nasal Cavity
The human nose differs in its anatomy and morphology between different racial and
ethnic groups. Therefore, the following anatomical description is a generalisation
and inter-racial variations exist. For completeness, structures that have synonyms
are followed by their alternate names in parentheses and italicised. Structurally the
nose can be divided into the external portion which is in fact termed as the nose and
the internal portions being the nasal cavities (nasal fossae; cavum nasi). The nose is
the only visible part of the respiratory system, protruding from the face, and lying
 
Figure 1.1 The overview of human respiratory system (Tu et al. 2013) 
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The human lung is estimated to contain half a billion alveoli and more than 2000 km of 
airways. The surface area is approximately 75-140 m2 in adults. The carbon dioxide and 
oxygen exchange process removes metabolic waste and maintains the body pH (Stone et al. 
1992). The alveoli are wrapped with pulmonary circulation whilst the bronchial veins bypass 
the pulmonary circulation and return the oxygenated blood to the heart via pulmonary veins. 
The alveoli are known to have a high solute permeability due to the thin epithelial barrier 
(alveoli epithelium is merely a single cell thick where the distance from the alveolar lumen to 
the bloodstream is <400 nm), an extensive vascularization and exhibits low proteolytic 
activity (Sahin-Yilmaz & Naclerio 2011). 
 
Drugs can be delivered to the lungs via inhalation or from the systemic circulation. The 
inhalation delivery route includes nasal and oral delivery depending on the site of interest. 
Delivering drugs into nasal cavity is used to unblock local congestion or to ameliorate 
allergic conditions whilst other pulmonary-related diseases such as asthma, tuberculosis, 
COPD, etc., the drugs are administer via oral inhalation to target tracheobronchial and 
pulmonary airways (Paranjpe & Müller-Goymann 2014; Agu et al. 2001; Adjei & Gupta 
1994). Although this route of drug administration for lung targeting is gaining more interest 
over these years, due to the highly efficient clearance mechanism of the human respiratory 
system, only small percentage of the emitted dose (ca. 10-15%) can be successfully deposited 
in the lung which results in short duration of resultant clinical effects (Labiris & Dolovich 
2003). To compensate, multiple day dosing which is far from ideal is required to treat 
pulmonary diseases such as asthma (Sturm et al. 2002; Stuart 1976). Another route for lung 
targeting drug delivery is from the systemic circulation through intravenous (i.v) 
administration. This mode of therapeutic administration is ideal to achieve immediate 
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therapeutic action which is recommended in cases of life-threatening asthma (Dhand et al. 
2014). This route of drug delivery is also useful when inhaled bronchodilators has failed after 
frequent doses. The following section will be discussed on the existing methods which have 
been used for lung-targeting drug delivery systems exploiting the intravenous route.  
 
1.1.1 Nanomaterial-mediated lung-targeting  
 
Nanoparticles (NPs) encompass structures with a size range from 1 – 100 nm (Figure 1.2). 
However, the prefix “nano” generally refers to particles of sizes from a few nm to 1000 nm 
(Cheng et al. 2017). The nanotechnology market is one of the fastest growing markets in the 
world. The market has increased from USD 339 billion in 2010 to more than USD 1 trillion 
in 2013, an average increased of 40-45% a year (National Science Foundation, 2014). For 
therapeutic applications, NPs are used to embed active agents e.g., drugs, imaging agents and 
genes. These active agents can be incorporated in the matrix of the particle or deposited on 
the surface of the nanomaterial (Hassan et al. 2017; Yin et al. 2017; Singh & W. 2009). This 
approach has been shown to provide controlled drug delivery across the membrane, improved 
targeting in certain cells, modify cellular transport and drug bioavailability (Bruni et al. 2017; 
Luk & Zhang 2015; Li et al. 2017; Kim et al. 2014; Masoudipour et al. 2017). Depending on 
the materials used, NPs can be categorised into soft vesicular carriers and rigid NPs. Size is 
an important feature that helps to determine the pharmacokinetic behaviour of the formulated 
NPs. In general, the small NP displays greater mobility and better cell penetration (Singh & 
W. 2009).  
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Figure 1.2 Particles categorized by size (Wilczewska et al. 2012)  
 
 
For examples, Desai and colleagues noted that NPs with the size of 100 nm showed a 2.5-
fold greater uptake rate than 1 µm and a 6-fold increased uptake compared to 10 µm 
microparticles in Caco-2 cells. In another study, Readhead et al. (2001) found that NPs 
penetrated throughout the submucosal layers of a rat intestinal loop model, whilst the 
localization of microparticles was mainly observed in the epithelial lining. When the size of 
particles gets smaller, it increases the area-to-volume ratio. Therefore, therapeutic agents 
embedded into small particles would be at or close to the particle surface which could lead to 
faster or immediate drug release (Singh & W. 2009). Smaller particles also have greater 
tendency to form aggregate during storage and upon delivery (Baalousha 2017). Hence, 
careful manipulation of the size of the NPs is important since this can significantly affect the 
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drug loading, drug release and also the stability of NPs in-vivo. NPs which are smaller than 7 
nm in hydrodynamic diameter are susceptible for renal clearance whilst NPs larger than 100 
nm can be excreted from the circulation by phagocytic cells (Sykes et al. 2014; Longmire et 
al. 2008). Apart from size, by coating the surface of NPs with biodegradable hydrophilic 
polymers e.g., polyethylene glycol (PEG), polyethylene oxide, polyoxamer, poloxamine and 
polysorbate 80 (Tween 80) was reported to enhance the drug loading of NPs (Biesta et al. 
2012; Qie et al. 2016). The addition of PEG to the NP surface (PEGylation) reduces the 
uptake of NPs by the reticuloenothelial system (RES), in which NPs are rapidly excreted out 
from the circulation to the liver, spleen or bone marrow, thus prolong NPs circulation time. In 
addition, PEGylation of NP surface decreases aggregation due to passivated surfaces (Jesse V 
Jokerst, Tatsiana Lobovkina 2012).  
 
There have been a number of studies that assessed the use of NPs for lung targeted delivery 
via i.v administration. For example, Xiang et al., (2007) studied the biodistribution of newly 
developed solid lipid nanoparticle (SLN) containing dexamethanose acetate (DXM). This 
optimized formulation consisted of 2 % pluronic F68, 110 mg of glycerol tristearate and 60 
mg DXM.  After intravenous administration, DXM-SLN showed a 17.8-fold increase in the 
lung uptake of DXM compared to DXM alone. This study suggested that SLN modified with 
F68 might provide a means for lung targeting drug delivery. Another study by Krueter and 
co-workers assessed the biodistribution of poly(methy-2-14C-methacrylate) nanoparticles. 
The organ distribution of the NP was measured from 0.5 up to 7 days after i.v injection. They 
reported that a maximum accumulation of the NP in the lungs was after 30 min (21.8%) and 
decreased to 13.2% after 7 days. Löbenberg et al. (1998) showed significant lung uptake of 
14C-azidothymidine bound to hexylcynoacrylate nanoparticles after i.v injection in rats 
compared to the uptake of the drug alone. The drug concentration in the lungs was reported to 
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be 18 times higher than control after 8 hours of administration. Given that growing interest in 
the application of nanomaterials in drug delivery, concerns have been raised regarding the 
possible risks that they may bring. There are mixed reviews on the toxicity of NPs with some 
studies reported that NPs are safe to be used whilst others showed that the uptake of NPs 
might eventually perturb cellular pathways and induce toxicity. NPs could easily find ways to 
enter the human body and cross the various biological barriers due to their small size and 
may reach the most sensitive organs (Yildirimer et al. 2011). It has been proposed that NPs of 
size less than 10 nm act like gas molecule and can enter human tissues easily and may disrupt 
the cell normal biochemical environment. This is an area that needs more work if 
nanomaterials are to be used to target the lung as it is a very sensitive organ that can, if 
insulted will result in perturbed respiration. Apart for toxicity issue, another major obstacle 




1.1.2 Prodrug-mediated lung targeting 
 
Prodrugs refer to derivatives of drug molecules that can be chemically converted into their 
active metabolites at the specified pharmacological site (Zhang et al. 2017; Zawilska et al. 
2013). This strategy relies on the unique physiological events which only occur at the site of 
interest (Rautio et al. 2017). This approach offers a more site-specific delivery of active 
molecules with a potential decrease in drug dosing requirements (Huttunen et al. 2011). 
 
A prodrug can be classified into (i) a bio-precursor prodrug i.e., a simple compound that can 
be chemically or metabolically transformed into its active compound and (ii) a carrier-linked 
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prodrug where the active metabolite is chemically linked to a carrier through covalent bond 
and release through biotransformation processes (Huttunen et al. 2011; Zawilska et al. 2013). 
The latter type of prodrugs can be further subclassified into bipartite and tripartite prodrugs. 
A bipartite prodrug is formed when the bioactive agent is directly attached to the carrier 
whilst for tripartite prodrugs, a spacer is used to link the carrier and the parent drug (Wu 
2009). Chemical groups such as carbamate, ester, phosphate, imine, carbonate amongst 
others are normally attached to the carrier so that a link could be formed between the active 
agent and the carrier (Rautio et al. 2008; Jornada et al. 2016) (Figure 1.3). A double prodrug 
is formed when two promoieties are attached to other and linked to the parent drug molecule. 
The two promoieties are usually different and normally cleaved through the non-identical 
mechanism. In some cases, two bioactive agents can be linked to each other forming another 
type of prodrug known as codrug where each molecule acts as the carrier to each other (Das 
et al. 2010). The use of prodrugs in drug delivery has been shown able to improve drug 
permeability and absorption, modify the distribution profile of active agents, provide 
protection from rapid metabolism and excretion as well as reducing toxicity-related problems 
(Huttunen et al. 2011; Rautio et al. 2017; Zawilska et al. 2013).  
 
In 2015, of 32 new drugs approved by FDA, 7 were identified as prodrugs (Rautio et al. 
2017). Fosphenytoin is a commercial product of prodrug containing an active molecule, 
phenytoin. Phenytoin is used clinically for anti-seizure treatment. Oxymethylene is used as a 
spacer to form a bridge between the phosphate ester and the amine group of phenytoin. The 
aqueous solubility of fosphenytoin is 7000 times greater than the drug alone and rapidly 
activated into phenytoin in the blood (t1/2 < 15 min in human) (Browne et al. 1996). Another 
example of a commercial product of prodrugs is dabigratan etexilate (brand name: Pradaxa) 
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which is administered orally for the prevention of stroke. The parent drug dabigatran is very 
hydrophilic (log P = -2.4) that results in very poor bioavailability after administration.   
 
 
Molecules 2016, 21, 42 2 of 31
solubility, stability, drug release and pharmacokinetics. Additionally, it can facilitate the accumulation
of a drug at the site of action and improve safety [9,10]. Bioprecursors are inactive compounds that
do not have a carrier and are rapidly converted to an active drug after metabolic reactions (normally
redox reactions) [5,8].
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Undesirable properties, including poor aqueous solubility, chemical instability, insufficient oral 
or local absorption, fast pre-systemic metabolism, low half-life, toxicity and local irritation are 
commonly resolved using the prodrug approach. In addition, problems related to drug formulation 
and delivery can also be overcome by using this strategy [1,11–13]. Occasionally, strategies such as 
particle-size reduction, solubilizing excipients, complexation agents and use of surfactants fail to 
improve the solubility in water profile and reduce toxicity to desirable levels [13,14]. For example, 
some surfactants used in parenteral formulations frequently have toxic effects such as anaphylactic 
reactions [14]. 
However, in some cases, low-solubility compounds yield false-positive results on in vitro assays 
due to non-specific binding [15]. Moreover, in clinical trials, low-solubility drugs can lead to 
precipitation and crystalluria, raising additional safety concerns. Poorly soluble drugs have recently 
been discontinued in clinical assays for this reason [15,16]. 
For these reasons, the prodrug approach presents a safe and effective strategy by which to 
improve the solubility of drugs. This review aims to present the latest strategies in prodrug design 
used to obtain water-soluble compounds for oral and parenteral uses. We selected research from the 
last ten years (2005 through August of 2015) showing increased solubility through the prodrug 
approach. In the literature search, we used the following terms: “water-soluble prodrugs”, “increased 
solubility prodrugs” and “enhanced solubility prodrugs” in published databases including PubMed, 
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Figure 1. In vivo bioactivation of prodrugs by enzymatic and/or chemical transformations.
Undesirable properties, including poor aqueous solubility, chemical instability, insufficient oral or
local absorption, fast pre-systemic metabolism, low half-life, toxicity and local irritation are commonly
resolved using the prodrug approach. In addition, problems related to drug formulation and delivery
can also be overcome by using this strategy [1,11–13]. Occasionally, strategies such as particle-size
reducti n, solubilizing excipients, complexation agents and use of surfactants fail to improve the
solubility in water profile and reduce toxicity to desi abl levels [13,14]. For example, ome surf ants
used in parenteral formulations frequently have toxic effects such as anaphylactic reactions [14].
However, in some cases, low-solubility ield false-positive results on in vitro assays
due to non-specific binding [15]. More , i li i l trials, low-solubility drugs can lead to
precipitation and crystalluria, raising ad iti al safet c cerns. P orly soluble drugs have recently
been discontinued in clinical assays for this reason [15,16].
For these reasons, the prodrug approach presents a safe and effective strategy by which to improve
the solubility of drugs. This review aims to present the latest strategies in prodrug design used to
obtain water-soluble compounds for oral and parenteral uses. We selected research from the last ten
years (2005 through August of 2015) showing increased solubility through the prodrug approach.
In the literature search, we used the following terms: “water-soluble prodrugs”, “increased solubility
prodrugs” and “enhanced solubility prodrugs” in published databases including PubMed, LILACS,
Scielo, Cochrane, Web of Science and Scopus.
2. Ester Prodrugs
The features of an ideal prodrug include the following: (a) hydrolysis resistance during absorption;
(b) weak or no activity; (c) aqueous solubility; (d) good permeability through the cells; (e) chemical
 
Figure 1.3 The bioactivation of prodrugs by enzymatic and/or chemical transformations in 
vivo (Jornada et al. 2016) 
 
 
Dabigratan etexilate is a bifunctional prodrug using carbamic ester and carboxylic acid ester 
attached to the two polar groups of dabigratan, amidinium moiety and carboxylic in order to 
mask their polarity and increase the drug lipophilicity. This results in absorption 
enhancement by 7% (Eisert et al. 2010). For anti-cancer treatm nt, many pro rugs are 
designed to be responsive t  the aberrant physiological conditions of the target tissue. Solid 
tumours mostly show selective enzyme expression, hypoxic cells and lower extracellular pH. 
The application of prodrugs for lung-targeting has been previously studied. Zhang et al., 
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(2015) used a prodrug-based nano-drug delivery system to encapsulate chemotherapy agents, 
paclitaxel (PTX) and carboplatin (CBP) for lung cancer treatment. PLGA-PEG-CBP prodrug 
was formed by attaching the carboxylic group of PLGA-PEG-COOH with the amino group 
of CBP. Then, the self-assembled nanoparticles combining PTX and PLGA-PEG-CBP 
(PTX/CBP NPs) were synthesized using solvent displacement technique. PTX/CBP NPs 
displayed the highest anti-cancer activity when tested in human non-small lung carcinoma 
cell line (H460). In a different study by Webster et al., (2015) showed a significant antitumor 
activity of bisphosphonates prodrugs when tested in human lung carcinoma (A549) cells. The 
synthesized prodrugs exhibited >250-fold increase in cancer inhibitory activity compared to 
the free bisphosphonates. Chung et al., (2006) assessed the antitumor activity of 20 
synthesized troxacitabine prodrugs in two non-small cell lung cancer cell line (A549 and 
SW1573). Their results suggested that prodrugs with long linear aliphatic chains (>8 CH2) 
were more potent than the free drug with the IC50 values in the nanomolar range. However, 
the pro-drug metabolism shows patient-to-patient variability and this is a significant concern 
for this targeting approach.  
 
1.1.3 Liposomes-mediated lung targeting 
 
Liposomes were first discovered in 1960’s. They are spherical in shape which are normally 
synthesized from cholesterol and natural non-toxic phospholipids. The advantageous of 
liposomes amongst others are biodegradable, non-immunogenic for both systemic and non-
systemic administrations, low toxicity and flexible (Allen & Cullis 2013; Akbarzadeh et al. 
2013; Sercombe et al. 2015). There are four main types of liposomes, conventional, 
PEGylated, ligand-targeted and theranostic liposomes (Figure 1.4).  
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Type one liposomes i.e., conventional liposomes were the first of its type to be developed. 
They are composed of a lipid bilayer that can be cationic, anionic or neutral phospholipid. 
The used of conventional liposomes has been shown to reduce toxicity through bioactivity of 
the drugs but however its therapeutic efficacy was limited by rapid elimination from the 
bloodstream (Gabizon et al. 2002). The second generation of liposomes, PEGylated 
liposomes were next introduced to combat the stability issue resulting in a more sterically-
stabilized liposomes with longer circulation time in the blood. Through incorporating PEG to 
the liposomes did prolong their blood circulation time, it appeared that this could reduce the 
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affinity of active agents with the intended targets (Northfelt et al. 1996). Ligand-targeted 
liposomes offer a more site-specific drug delivery. However, this approach can only be 
applied to particular types of cells that selectively express of over-express specific ligands 
(Puri et al. 2009). The ligands incorporated in liposomes could be receptors or cell adhesion 
compounds. However due to poor pharmacokinetics and immunogenicity, the use of ligand-
specific liposomes often results in poor enhancement or no therapy enhancement at all. 
Considering the problems above, the newer generation of liposomes are designed using a 
combination of the previous designs to improve their targeting delivery.  
 
Meng and Xu (2015) assessed the organ distribution of pirfenidone-loaded liposomes for 
lung targeting after i.v administration in mice. Their results showed a sustained delivery and 
an improved lung uptake of the liposomes formulation compared to the free drug solution. 
However, the histopathological data showed possible alleviation of lung injury of the 
liposomal formulation due to the physical trapping of the liposomes in the vascular network 
of the lung. Another study by Zhang et al. (2009) investigated the injectable levofloxacin 
loaded liposomes to target the lung for the treatment of pulmonary inflammation. The 
liposomal formulation was prepared using ammonium sulfate gradients method. The size of 
the formulated liposomes was relatively uniform (7.424±0.689 µm) with a zeta potential 
(+13.11±1.08 mV). The entrapment efficiency of levofloxacin-loaded liposomes ranged from 
82.19% to 86.23%. The in-vivo results showed a prolong elimination half-life of the 
liposomal formulation compared to the free levofloxacin solution after i.v injection in rabbits. 
A change in the bio-distribution profile of levofloxacin-loaded liposomes was also observed 
where a significant lung targeting of the molecule was achieved using the liposomal 
formulation compared to the organ distribution profile of free levoflaxcin solution. However, 
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liposomes are not very physically stable and this can be worsened upon the attachment of 
ligands and incorporation of drugs and this hinders this approach. 
 
1.1.4 Ion-paired in drug delivery 
 
Approximately half of the clinically used drugs are ionisable at physiological pH (Patel et al. 
2016). This permits the ionized forms of the drugs to form links with the other charged 
species through a chemical process known as ion-pairing (Song et al. 2013). Ion-pairing can 
be described as the association of the oppositely charged molecules in solution (Figure 1.5) 




: Ionized drug 
: Ionized counter-ion
Crystalization in favourable 
conditions (solid phase)
Liquid phase






Figure 1.5 A diagrammatic representation of “salt form” and an “ion-pair” 
 
 
In solution, three types of ion-pair could exist depending on the distance of the interaction 
which is limited by solvent permittivity (Figure 1.6). The production of a drug-counter ion 
ion-pair often results in the formation of relatively neutral species and hence improves the 
drug partitioning of polar drugs into the lipophilic membranes. Thus this approach can 
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improve absorption without the need to disrupt the membrane integrity (Nam et al. 2011; W. 
Wang et al. 2017). The pH partitioning theory suggested that only the unionized form of drug 
molecules can easily penetrate the biological membranes whilst the charged species do not 
pass the membranes (Shore et al., 1957). Once a drug is ion-paired with a counter-ion, they 
behave as a single unit (Marcus & Hefter 2006). This pair of oppositely charged ions is held 
together by long-range, non-directional electrostatic forces which making ion-pairing slightly 
different from covalent complexes. In case of complexes, they are formed through short-
range, directional donor-acceptor (coordinative) covalent bonding (Haas & Franz 2010). In 
addition, the formation and dissociation constants of most ion-pairs are weaker compared to 






Figure 1.6 A schematic representation of ion-pair types: (A) solvent separated (2SIP), (B) 
solvent shared (SIP) and (C) contact ion-pair (CIP). 2SIP refers to double solvent-separated 
ion-pair, SIP occurs when only a single layer of solvent which is shared between the ions and 
CIP when no solvent exist between ions (Marcus & Hefter 2006). 
 
 
The ion-pairing approach is simple in principle, but due to a low physical stability, 
quantification and tracking these complexes is difficult. When ion-pairs distribute in the 
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body, they will almost certainly dissociate to into their parent ions and eliminated 
individually (W. Wang et al. 2017; Zhao et al. 2017b). Therefore, this strategy represents a 
novel way to alter the physicochemical properties of a drug, such as solubility or partitioning 
behavior and receptor interactions without actually altering the molecular structure or the 
pharmacological activity of the API on a temporary basis. However, the major setback of this 
approach is that the non-covalent bonding might be too weak in solution to facilitate 
membrane permeation.  
 
It is experimentally difficult to measure ion-pairs lifetimes. However, previous studies have 
shown using simple electrolytes that their lifetimes ~1 ns but drug ion-pairs have not 
undergone a similar analysis process (Buchner et al. 2003). It is hypothesized that a high 
stability constant of the ion-pair in aqueous (K11aq) medium is required for the ion-pair 
formulation to remain intact when it enters the biological system due to binding competition 
from the endogenous ions (Marcus & Hefter 2006). The existence of an ion-pair can be 
questioned when the association constants is too low (< 2 M-1) even though previous studies 
have shown association when constants are even lower, e.g., Me4+Cl- (0.29 M-1) and Me4+Br- 
(0.83 M-1) (Geng & Romsted 2005). The proposed ideal log D of the ion-pair for a facilitated 
passive membrane permeation was between 2-5 (Miller et al., 2009). It appears that the 
physicochemical properties of both the drug and the counter-ion strongly influenced the 
ability of the formulated ion-pairs to alter the drug behavior (Samiei et al. 2014; Samiei et al. 
2017; Elshaer et al. 2014). In general, drugs lipophilicty can be increased by pairing with 
lipophilic counter-ions. This approach has been studied as an alternative approach to alter the 
transport of ionisable drugs across biological barriers (Table 1.1).  
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For lung-targeting delivery, Zara et al. (1999) assessed the the pharmacokinetics of 
doxorubicin incorporated as ion-pair into solid lipid nanospheres (SLN) was compared with 
that of the commercial solution of the drug in rats. Animals injected with SLN carrying 
doxorubicin exhibited higher lung uptake of the drug compared to animals treated with 
commercial doxorubicin solution (Adriablastina). A lower doxorubicin concentration in liver, 
heart and kidney was also found in SLN-treated animals. This study suggested that SLN 
increased the area under the curve (0-180 min) of doxorubicin compared to conventional 
doxorubicin solution and led to a different body distribution profile. Patel et al., (2016) 
showed that the selection of the counter-ions was crucial in determining the biological 
behaviour of the parent drug molecule. The results from their study showed a superior 
bronchodilator effect (p <0.05) of salbutamol when presented with excess 1-hydroxy-2-
naphthoate (1H2NA) counter-ion compared to effect of salbutamol base. This affect was 
assigned to the effect of ion-pairing formation. Ion-pairing formoterol or salmeterol with the 
counter-ions aspartate, maleate, fumarate, and 1H2NA showed no effect on the drugs to 
reduce airway resistance in-vivo. For active lung-targeting, one interesting group of 
molecules that could form ion-pair for lung-targeting drug delivery are the polyamines.  
 
1.2 Polyamines  
 
Polyamines (PA) are organic compounds bearing two or more amino groups –NH2. 
Endogenous polyamines e.g., putrescine (NH2(CH2)4NH2), spermidine 
(NH2(CH2)3NH(CH2)4NH2)  and spermine (NH2(CH2)3NH(CH2)4NHCH2)3NH2) are derived 
from intracellular biosynthesis whilst exogenous polyamines could be obtained from diet and 
luminal bacteria (Jr. Casero & Woster 2010). PA are present in almost all cells where they 
are actively involved in gene expression, cell proliferation, cellular stress and human disease 
(Poulin et al. 2012; Miller-Fleming et al. 2015; Jr. Casero & Woster 2010). The polyamine 
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transport system (PTS) has been previously described in bacteria and single celled 
eukaryotes. However, in mammals, the system is still not been fully characterized. To date, 
no PA specific transporter has been identified. Poulin et al., (2012) proposed that an 
endocytic mechanism might be involved in PTS in animal cells. It has also been suggested 
the involvement of SLC7 (Lys/Arg/Orn permeases), CCC9 (an inorganic ion transporter) and 
OCT6 (cation/anion/zwitterion transporter) in PAs uptake in mammalian cells.  
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Table 1.1 Previous studies on the use of ion-pairing in drug delivery 
Drug Therapeutic 
function 











• Significant increase of IND cell 
permeability when paired with 
the respective counter-ions 











• Human epithelial 
colorectal 
adenocarcinoma 
(Caco-2) cells  
 






• Arginine and phenazopyridine 
enhanced the apparent 
permeability of alendronate by 
14- and 26-fold in the PAMPA 
model and 6.5- and 4.4-fold 
across caco-2 cell monolayers, 
respectively. 
 
(Samiei et al. 2017) 
Amifostine 
(AMS) 
Anti-cancer Succinic acid, 
phtalic acid, 
benzoic acid 




• 1.6-fold increase of log P of the 
drug when paired with phtalic 
acid whilst for benzoic acid and 
succinic acid the values 
increased by 1.2 and 0.75-fold 
respectively.  
 
• Significant increase of AMS 
PAMPA permeability in the 
presence of phthalic acid (42-
fold), benzoic acid (37-fold) 
(Samiei et al. 2014) 
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Anti-cancer Arginine • Rabbit nasal 
mucosa 
• The partition coefficient of 
MTX was 24 times greater in 
the methotrexate-L-arginine ion 
paired systems than that of the 
methotrexate system without L-
arginine.  
 




Anti-cancer Organic amines • Rat skin • Increased of skin permeation 
through ion-pair formation. 
 















• Rat jejunal 
• Enhanced in the apparent 
permeability (Papp) of both 
compounds across Caco-2 cell 
monolayers in a concentration-
dependent manner in the 
presence of HNAP. 
 
• Significant enhancement in the 
rat jejunal permeability of ZHE 
by the addition of HNAP in a 
concentration-dependent 
manner (zero without HNAP to 
4.0 × 10-5 cm/s with 10 mM 
HNAP). 
 





Organic amines • Rabbit skin • The permeation of ZAL was 
significantly improved with 
alkylamines and 
cycloalkanolamines but 
(Cui et al. 2015) 
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significantly retarded with 
alkanolamines. 
Insulin  Anti-diabetic Amino acids • Human buccal 
epithelium 
(TR146) cell layers 
• Basic amino acids improved 
insulin solubility in water while 
200 and 400 µg/mL lysine 
significantly increased insulin 
solubility in HBSS. 
 
• Significant improvement in the 
insulin permeation: 10 µg/mL 
of lysine (p < 0.05), 10 µg/mL 
of histidine (p < 0.001), 100 
µg/mL of glutamic acid (p < 
0.05), 200 µg/mL of glutamic 
acid and aspartic acid (p < 
0.001) without affecting cell 
integrity. 
 
(Iyire et al. 2016) 
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1.3 Aims and scope of thesis 
 
In healthy cells, the pulmonary tissue has been reported to express a more active polyamine 
uptake system (PTS) compared to cells derived from other tissues (Hoet & Nemery 2000). 
Considering that at physiological pH, PAs primarily exist as protonated polycations, there is a 
great potential of using polyamine ion-pairing to target drug into the lung from the 
pulmonary circulation when administered intravenously. Different approaches have been 
studied using polyamine to target drug to specific cells before but polyamine ion-pairing 
mediated active lung targeting is yet to be tested (Figure 1.7). 
 
Makino et al. prepared polystyrene microspheres of 1 mm
diameter with different surface groups such as primary amine,
sulfate, hydroxyl, or carboxyl groups. Their results showed
that the alveolar macrophages trapped most effectively poly-
styrene microspheres with primary amine groups, whereas car-
boxyl groups bearing microspheres were taken up by alveolar
macrophages to a slightly lesser extent, and other micro-
spheres were taken up in smaller amounts. They concluded
that microspheres having soft surfaces are easily accessible to
alveolar macrophages, and effectively trapped by macro-
phages. Alveolar macrophage uptake undoubtedly increases
drug delivery to lungs.
Cisplatin (cis-diaminedichloroplatium [CDDP]) is one
of the most potent anticancer agents that cause several side
effects, including renal disturbances, nausea, vomiting and
auditory toxicity. Huo et al. [22] prepared cisplatin-loaded
poly(lactic-co-glycolic) acid (PLGA) microspheres and studied
their pharmacokinetics and tissue distribution in rabbit.
Their results suggested a significantly higher concentration
of CDDP in lung (212 µg/g, 15 min) than those of other
tissues and blood. Compared with CDDP intravenous injec-
tion, the drug concentration of cisplatin in lung after intrave-
nous injection of CDDP-PLGA-MS was enhanced from
1.37 to 212 µg/g (15 min). Carboplatin (CPt) is a potent
antitumor drug used for many types of cancer treatment,
including pulmonary small-cell carcinoma, carcinoma of
ovary and testis, and epithelium carcinoma of the head and
neck. Lu et al. [23] prepared carboplatin-loaded gelatin micro-
spheres having arithmetic mean diameter 13.20 µm with 98%
of the microspheres ranging from 5.0 to 28.6 µm and found
that the targeting efficacy (te) of lung increased by a factor
of 9.4 compared with spleen and 90.5 compared with liver.
Compared with the original drug CPt, the targeting ratio of
lung [(te)NS/(te)S] increased by a factor of 11.8, compared
with kidney, 36.5, compared with liver, and the ratio of
peak concentration in lung (Ce) increased by a factor of
4.1 compared with CPt and suggested that microencapsula-
tion improved the antitumor effect of CPt (S-180 lung
neoplasm models) (Figure 2).
Recently, Yang et al. [24] developed porous PLGA micro-
spheres by using ammonium bicarbonate (ABC) as an effer-
vescent porogen agent, to avoid macrophage uptake, and to
enhance the drug encapsulation efficiency. They found that
microparticles prepared with 7.5% w/w (ABC/PLGA) had a
mass median aerodynamic diameter (MMAD) of 4.0 ±
1.2 µm and fine particle fraction (FPF) of 32.0 ± 9.1%, depos-
ited at the Andersen Cascade Impactor (ACI) stage. The highly
porous large particles avoided phagocytosis by macrophages,
while non-porous small particles were quickly taken up by
the macrophages. Enrofloxacin has a broad spectrum of
antibacterial activity against Gram-negative bacteria, Gram-
positive bacteria, and mycoplasma species in animals [25-27].
Traditional enrofloxacin formulation exerts adverse effects,
such as drug residues, resistant bacteria and allergic hypersensi-
tivity reactions [28-30]. Tang et al. [31] prepared enrofloxacin
microspheres by emulsifying with gelatin and liquid paraffin,
and studied their pharmacokinetics and lung targeting charac-
teristic in dogs after intravenous administration and found
that the half-life of the distribution phase was reduced by
77.78%, the half-life of the elimination phase was lengthened
from 5.15 to 33.86 h, and the rate of body clearance in the
lung was shortened by 55.72% as compared with marketed
Enrofloxacin injection (Baytril, Bayer Healthcare, USA). The
targeting ratio to the lung (Te(microsphere)/Te(Baytril) increased
by a factor of 1.77 compared with liver and 3.51 compared









Figure 1. Various carriers for lung targeting.
Kurmi, Kayat, Gajbhiye, Tekade & Jain

































Figure 1.7 The existing startegies to target drug to the lung. Picture was taken from Serombe 
et al (2015) with some modifications made by the author. 
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The aim of this thesis was to evaluate the use of polyamine ion-pairing approach for the 
development of an intravenous active lung-targeting delivery of theophylline. To address this 
aim, the following objectives were set: 
  
1. To assess the binding of theophylline with a selection of polyamine counter-ions. 
Since the ability of a molecule to permeate through biological barrier is highly 
dependent on its physicochemical properties, changes in the physicohemical 
properties of theophylline on aqueous solubility, lipophilicity and chemical stability 
upon forming ion-pair with polyamines was evaluated. 
2. To characterize cyclodextrin-theophylline-polyamine complex. It is known that the 
issue with the ion-pairing approach is the weak non-covalent interaction between the 
ions could result in break downs prior to reaching the target site. Thus, cyclodextrin 
was used to try to stabilize the theophylline-polyamine ion-pair association. 
Characterization of cyclodextrin-theophylline-polyamine complex was performed 
using NMR and a 3D modelling technique was used to predict the interaction between 
cyclodextrin and the ion-pair. 
3. To assess the effect of delivery co-solvent on the complex and to study pH-induced 
dissociation of the ion-pair. It is known that the solvent properties e.g., polarity 
influenced complex formation. An ideal solvent could thus enhance the ion-pair 
stability hence slow down its break down in solution. 
4. To assess the in-vitro cytotoxicity and cellular uptake of cyclodextrin-theophylline-
polyamine complex in lung cell
 CHAPTER 2 





This chapter characterized the strength of association between theophylline and a selection 
of amine counter-ions. In addition, it evaluated how the theophylline-amine interactions 
influenced the lipophilicity and aqueous solubility of the drug. A series of polyamines, 
increasing in the number of amine functional groups were used as the ion-pairing agents: 
ethylenediamine, spermidine and spermine with a monoamine, ethylamine, as a control. The 
chemical stability of the drug when mixed with excess counter-ion and stored up to 4-week 













  25 
2.1 Introduction 
 
The natural polyamines are ubiquitous in all prokaryotic and eukaryotic cells where higher 
accumulation of these polycations has been reported in animal lung cells (Hoshino et al. 
2005; Hoet & Nemery 2000; Saunders et al. 1989; Smith et al. 1990; Minois et al. 2011). At 
physiological pH, these poly-cations are charged which allows them to associate non-
covalently with other negatively charged molecules (Hoshino et al. 2005; Hoet & Nemery 
2000). This interactive potential of polyamines makes it possible for them to form ion-pair 
with ionisable xenobiotics in a manner that could facilitate their uptake into the lung.  
 
Using theophylline as a model drug, the present study assessed the impact of forming ion-
pairing with polyamines on the biopharmaceutical properties of the drug. Theophylline is a 
well-established bronchodilator for the treatment of asthma and chronic obstructive 
pulmonary disease (COPD) (Malamatari et al. 2016). Delivering theophylline through 
inhalation to patients was found to be irritating and ineffective. In clinic, injectable 
theophylline (aminophylline) is used to treat acute severe asthma. Aminophylline is a 2:1 
theophylline:diethylamine salt used to overcome theophylline poor solubility so that i.v 
administration of the drug is possible (Barnes 2010). Theophylline has a narrow therapeutic 
index (10 - 20 ug mL-1) and unspecific distribution in the body after administration often 
leads to poor side-effect profile, which is normally manifested by nausea, dizziness, 
vomiting, tachycardia, arrhythmias and seizures (Powell et al. 1978; Jusko 1984; Nakura et 
al. 1998; Malamatari et al. 2016). Despite its poor side-effect profile, theophylline is still 
extensively prescribed worldwide, because it is inexpensive. When administered (both orally 
and intravenously) to rats, theophylline was found to be almost evenly distributed in liver, 
muscle, lung, spleen and heart where higher theophylline distribution was found in liver and 
kidney (Jusko 1984; Powell et al. 1978; Gabrielsson et al. 1984). It was also reported that 
  26 
theophylline can cross the placenta and distributed in the organs of the fetus of the pregnant 
rats (Gabrielsson et al. 1984). With the aim to reduce these side effects, there is a need to 
reformulate this API for targeted lung delivery upon intravenous delivery. One interesting 
approach is by manipulating the PTS to target theophylline delivery to the lung. This can be 
achieved by forming theophylline ion-pairs with polyamines which are the PTS substrate. 
Previous studies have shown the success of using ion-pairing as a strategy to improve the 
transport of ionisable drugs across the skin (Wang et al. 2008), nasal (Ivaturi & Kim 2009) 
and intestinal (Ester et al. 2012) mucosa but has yet  to be tested for the lung targeting 
system.  
 
Ion-pair describes the formation of a temporary, spontaneous, non-covalently bound complex 
in solutions (Samiei et al. 2017). The intermolecular association between the molecules 
changed the physicochemical features of the parent drug which affected the molecules 
absorption (Zhao et al. 2017a; W. Wang et al. 2017). A study by Ivaturia and Kim (2009) 
demonstrated a 3-fold increase of methotrexate flux across rabbit nasal mucosa in-vitro when 
combined with a counter-ion, L-arginine when compared to the flux of the drug alone. 
Another study by Samiei et al., (2014) showed increased in the permeability of amifostine 
across a lipophilic membrane in the presence of the counter-ions: phthalic acid (46-fold), 
benzoic acid (37-fold) and succinic acid (10.5-fold) resulting from the ion-pair formation. 
The magnitude of change in the apparent permeability value (Papp) of the drug was found to 
be dependent on the concentration of the counter-ion applied. The permeability of 
indomethacin was also found to be counter-ion concentration dependent when studied in 
Caco-2 monolayers (Elshaer et al. 2014). In this study, L-arginine and L-lysine were used as 
the counter-ions. 
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Drugs can be absorbed through membranes via a considerable number of routes. Amongst 
those, passive transport is the most common one (Sugano et al. 2010). The ability of a 
molecule to passively permeate through the biological membranes normally depends on the 
non-polar fraction of the molecules as well as the physicochemical properties of the permeant 
such as molecular size, hydrogen bond capacity, lipophilicity, pKa and solubility (Liu et al. 
2011; Nam et al. 2011). In case of carrier-mediated transport, this usually occurs through site-
specific interactions (Sugano et al. 2010). Lipophilicity can be measured by determining the 
distribution of a molecule between an organic layer (normally n-octanol) and an aqueous 
layer (Kah & Brown 2008). The partition coefficient (log P) obtained can be used to predict 
the lipid affinity of a molecule. In case of ionisable drugs, the apparent distribution 
coefficient (log DpH, equation 2.01) is often used instead of log P which is only valid for a 
single species.  
 
log DpH = log (fN . PN + fI . PI)          (2.01) 
 
Where fN and fI are the molar fractions of the neutral and ionized forms, and PN ad PI are their 
respective partition coefficients. A molecule with log D7.4 between 0 – 1 may demonstrate an 
ideal balance between solubility and permeability, < 0 – high solubility with susceptible to 
renal clearance, > 5 – poor solubility, bioavailability and can cause erratic absorption (Andres 
et al. 2015). The association between an ionized drug [A-] with the oppositely charged 
counter-ion [B+] normally results in neutralizing the charge of the parent drug that often 
improves the lipophilicity of the molecule. Nam et al., (2011) demonstrated an increase of 
risedronate (RS) (log PRS = -3.6) lipophilicity in the presence of the counter-ions: L-arginine 
(ARG) (log PARG = -4.2), L-lysine (LYS) (log PLYS = -3.2) and diethylenetriamine (DIE) (log 
PDIE = -1.73) by 8.9%, 12.0% and 2.1%, respectively when compared to the lipophilicity of 
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the drug alone. Contrary to this, ElShaer et al., (2014) demonstrated a decreased of 
lipophilicity of indomethacin (IND) (log PIND = 4.2) when the counter-ions L-arginine and L-
lysine were presence in excess. They postulated that the drop of lipophilicity of the drug 
could be due to high hydrophilicity of the counter-ions. In another study, it was found that the 
change of the drug’s lipophilicity when formed the ion-pairs was not solely influenced by the 
lipophilicity of the counter-ions, but also by the association strength and overall charge 
reduction over the drug molecule (Samiei et al. 2014).  
 
In our case, we expect an increase in the solubility of theophylline which in return might 
diminish its lipophilicity when mixed with the amine counter-ions since all selected counter-
ions are very hydrophilic (Table 2.1). Theophylline has a poor solubility but its solubility 
increased considerably when combined with diamine, ethylenediamine (Aslaksen et al. 
1981). However, the magnitude of change in the physicochemical properties of theophylline 
when the drug forms ion-pairs with the amines might also be influenced on the affinity of the 
drug to bind to the counter-ions since the counter-ions are different in the hydrogen bonding 
capacity. Direct analytical techniques for binding measurements are normally reported for 
metal-ion complexes, metal-protein complexes and protein-protein complexes (Gromiha & 
Yugandhar 2017; Alberti et al. 2016; Kocyła et al. 2015) but rarely studied for ion-pair 
complexes.  
 
The aims of this chapter were to assess the theophylline-amines binding in water and to 
investigate the consequences of the ion-pairing process on the lipophilicity, solubility and 
chemical stability of theophylline. The binding association between theophylline and a 
selection of different amine counter-ions in water was assayed by means of Fourier 
Transform Infrared spectroscopy (FT-IR) and High Performance Liquid Chromatography 
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(HPLC). The physicochemical properties of theophylline and the respective counter-ions 
used in this study were summarized in (Table 2.1). The pH of all mixtures was adjusted to 9.6 
to mimic the normal formulation pH of aminophylline1. We specifically used 9.6 + 0.1 as our 
working pH to maximize the percentage of ionized theophylline which then provides the 
optimum condition for the ion-pairing process to take place between the oppositely charged 
molecules. The IR spectroscopy was used for this purpose due to its high sensitivity that can 
detect the changes in the chemical composition of small molecules which provides the 
insights of different levels of structural features apart from short measuring time, cost-
effective and low amount of sample required (Nafisi et al. 2012; Kim et al. 2010; Malathi 
2012).  
 
The reversed phase (RP)-HPLC approach is based on substance partition between a non-polar 
stationary phase and an aqueous. This method is cheap and cost-effective. The retention of 
theophylline is governed by the partition between the aqueous mobile and stationary phase. 
When the amines counter-ions were added to the mobile phase, there is an additional 
contribution to the drug retention due to the ion-pairing process. The changes in the retention 
of theophylline will then reflect the degree of intermolecular interactions formed between the 
drug and the level of amines counter-ions presence in the mobile phase.
                                                
1 Aminophylline (a 2:1 complex of theophylline:ethylenediamine) is the commercial product of injectable 
theophylline. The USP solution of aminophylline has a pH between 8.5 – 9.7. 
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Table 2.1 Physicochemical properties of theophylline and the respective counter-ions used in the present study. pKa - acid dissociation constant; 
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EA 45.08 10.60b - 0.13 NH2  
EDA 60.10 pK1 = 10.21
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pK1 = 10.89d 
pK2 = 9.81d 
pK3 = 8.34d 




pK1 = 10.98d 
pK2 = 10.09d 
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2.2 Materials  
 
Theophylline (THE) (anhydrous, > 99%), spermine (SP) (> 99%), spermidine (SPD) (> 
99%), ethylamine (EA) 70 wt. % in H2O, ethylenediamine (EDA) (> 99%), 1-octanol, 
deuterium oxide (D2O) (D atom > 99%), sodium hydroxide (NaOH), hydrochloric acid 
(HCl), sodium chloride (NaCl) were purchased from Sigma Aldrich, UK. All reagents for 
HPLC analysis were HPLC grade.  
 
2.3 Methods 
2.3.1 Fourier Transform Infrared spectroscopy (FT-IR) binding studies 
 
The Infrared (IR) conditional binding constant (pKFT-IR) of theophylline-amines complexes 
were assessed using a universal liquid cell system (Omni-Cell, Specac Ltd, UK) fitted with 
CaF2 windows and 0.025 mm mylar spacer (Specac Ltd, UK) was used for the absorbance 
measurements. D2O was employed as the solvent for the measurements as it showed less 
interference with the IR absorption of theophylline compare to H2O. The absorbance spectra 
of 0.015 M theophylline at 1:0 – 1:20 theophylline-amines molar ratios were recorded within 
the range of 1725 – 1500   cm-1 using D2O pH adjusted to 9.6 + 0.1 using NaOH/HCl. NaCl 
was added when necessary to keep a constant ionic strength (0.5 M) in all mixtures. All 
spectra were subtracted with the spectra of the blank solutions and baseline corrected. The 
blank solutions refer to the exact compositions of the test solutions in the absence of 
theophylline. Changes in the peak absorbance ratio at ca. 1530/1551 cm-1 were calculated 








1530 cm-1 as the complexed theophylline. The change in the IR ratio was used to determine 
the percentage of theophylline bound as a function of amine concentration (Figure 2.1). The 
percentage of theophylline bound vs –log[amine]free were plotted and fitted with a regression 
model (GraphPad Prism7) to determine the FT-IR conditional binding constant (pKFT-IR) of 
theophylline-amines complexes in water. The percentage of theophylline bound to amine 
counter-ion was calculated using Equation 2.02.  
 
 
 %	theophylline	bound = 	 (12	–	4)674     x 100         (2.02) 
 
 
Where A represented the maximum abs ratio of theophylline peaks at ca. 1530/1551 cm-1 
when mixed with the counter-ions. B indicated the abs ratio of theophylline peaks at ca. 
1530/1551 cm-1 of free theophylline. X1 indicated the abs ratio of theophylline peaks at ca. 
1530/1551 cm-1 when mixed with a known concentration of counter-ion. The concentration of 
free amine was calculated using Equation 2.03. 
 
 amine &'(( M = 	 [amine]./.	 M 	– ([theophylline]./.	(M)	x	(%	.;(/<;=>>?@(	A/B@CDEE ))     (2.03) 
 
 
Where [amine]free represented the free unbound amine to theophylline. [amine]tot referred to 
the initial concentration of amine in the mixture. [theophylline]tot referred to the initial 
concentration of theophylline (0.015 M). The value for [amine]free was calculated with an 
assumption that theophylline formed a 1:1 ionic complex with the amine counter-ion. All 
spectra were recorded using a Spectrum One spectrometer (Perkin Elmer Ltd, UK) and 








The resolution was set at 4 cm-1 and 12 scans were performed for each measurement. 
Experiments were repeated in triplicate and the results were presented as mean + SD. 
 
2.3.2 High Performance Liquid Chromatography (HPLC) binding studies 
 
The HPLC conditional binding constant (pKHPLC) of theophylline-amines complexes in water 
at pH 9.6 + 0.1 was assessed using a HPLC system equipped with a pump (Waters 600-MS 
system controller) that was connected to an automated sample injector (Waters 717-plus auto 
sampler) and coupled with a UV detector (Waters 2487 Dual λ abs detector). The HPLC 
system was connected to a computer installed with a Millenium software that was used to 
record and analyse all chromatograms. A Phenomenax Kinetic 5 µ Biphenyl 100 A 250 x 4.6 
mm HPLC column (Phenomenax, UK) was used as the stationary phase. The mobile phase 
used was 100 % water in which increasing concentrations of amines were added, pH adjusted 
to 9.6 + 0.1 using HCl. All solutions were filtered through 0.45 µm pore size nylon 
membrane filter and sonicated for 1 hour. The flow rate was set at 1 mL min-1 and the UV 
detector was set at 273 nm. Briefly, 10 µL of 0.5 mM theophylline was injected into the 
system and the change of theophylline retention time when treated with increasing 
concentrations of amines was recorded. The change in theophylline retention in the column 
was used to determine the percentage of theophylline bound as a function of amine 
concentration. The percentage of theophylline bound vs –log[amine]free, was plotted and 
fitted with regression model (GraphPad Prism7) to determine the pKHPLC of theophylline-
amine complex. Experiments were repeated in triplicate and the results were presented as 









2.3.3 Water-octanol distribution coefficient (Log Do/w) studies 
 
The Log D protocol used in the study was similar to the protocol reported by Miller et al., 
(2010) and Samiei et al., (2014). Equal volumes of 500 mL of deionized water and 1-octanol 
were thoroughly mixed in a separating funnel to saturate the two phases. The mixture was 
subsequently allowed to stand for 24 h prior to use to enable complete phase separation. The 
organic upper-phase (UP) and aqueous lower-phase (LP) were separated shortly before use. 
The apparent octanol-water distribution coefficient (Do/w) of theophylline was assessed in the 
excess amines solutions (theophylline-amine molar ratios: 1:0 – 1:100). Theophylline was 
mixed with the amines in the 5-mL total volume of LP, pH adjusted to 7.4 and 9.6 (± 0.1). 
Subsequently, an equal 5-mL of UP was added to each solution. The mixtures were left to 
mix in a water bath with gentle stirring for 48 h at 37 oC. The two layers were later separated 
and the aqueous layers were further analysed using UV spectrophotometer (Lambda 2S, 
Perkin Elmer, UK) to determine the concentration of theophylline in the aqueous phase, 
[theophylline]aq. The concentration of 0.05 mM theophylline used throughout the 
experiments was sufficiently low so that it can be presumed that the solute was in ‘infinite 
dilution’ in each phase that solute-solute interactions were minimal (Kah & Brown 2008). 
The concentration of theophylline in the organic layer, [theophylline]oct was calculated using 
Equation 2.04. 
 [theophylline],-./0,1 = 	 [theophylline]404.4/1-	[theophylline]/678,79		       (2.04) 
 









Log	D&/( 		 = Log	 	[&'(&)*+,-(&'(&)*+	./*'0/122&(*]4567849			 &'(&)*+,-(&'(&)*+	./*'0/122&(* 7:;<4;=			       (2.05) 
 
2.3.4 Solubility studies 
 
Excess theophylline was added to a series of amines solutions ranging from 0.0 – 2.0 M. The 
mixtures were stirred in a water bath for at least 48 h at 37 oC to allow equilibrium to be 
reached, then filtered and assayed using UV (Lambda 2S, Perkin Elmer, UK) to determine 
the concentration of theophylline. The final pH of the mixtures was adjusted to 7.4 and 9.6 
(±0.1) using HCl. Experiments were repeated in triplicate and data was presented as mean ± 
SD. 
 
2.3.5 HPLC assay method verification 
 
A Phenomenax Kinetic 5 µm Biphenyl 100 A 250 x 4.6 mm HPLC column (Phenomenax, 
UK) was used as a stationary phase. The mobile phase used was a mixture of 90:03:07 
water:methanol:acetonitrile H2O:MeOH:ACN (v/v), pH 4. All solutions were filtered through 
0.45 µm pore size nylon membrane filter and sonicated for 1 hour. The injection volume was 
10 µL and the flow rate was set at 1 mL min-1. The UV detector was set at 273 nm. To verify 
the method was ‘fit-for-purpose’ standard solutions of 5, 25, 50, 75 and 100 µg mL-1 of 
theophylline were prepared using the mobile phase and assayed using HPLC. The mean peak 
area vs concentration (n = 5) was plotted for the five concentrations to generate the 
calibration curve that was fitted with a regression model (GraphPad Prism7). The peak 









!" = $%.%'() 		     (2.06) 
 
where W0.05 is the width of the peak at one-twentieth peak height above peak baseline, d is 
the distance between the perpendicular dropped from the peak maximum and the leading 
edge of the peak at one-twentieth of the peak height. A peak symmetry of 1 was considered 
ideal as this represents a perfectly symmetrical peak. The theoretical plates which indicate 
column efficiency was calculated (n = 15) using equation 2.07 where, t is the retention time 
of peak and Wh/2 equals the width of the peak at half the peak height.  
 
! = 16	 &'()/+	 ,		          (2.07) 
 
 
The LOD (the lowest concentration of an analyte in a sample that can be detected but not 
necessarily quantified) and the LOQ (the minimum injected amount of analyte that gives 
precise measurements) was calculated according to equations 2.08 and 2.09, respectively.  
 
LOD = YB + 3sB           (2.08) 
LOQ = YB + 10sB           (2.09) 
 
sB is the standard error of the y estimate and YB is the intercept from the regression 
equation.  The precision of the HPLC method was determined by the repeatability (intra-day) 








evaluating the variance between three standard curves assayed from the same standard 
solutions (five injections per standard). The intermediate precision of the test molecules was 
determined by comparing three calibration curves using independently prepared standard 
solutions (five injections per standard) on three separate days. The accuracy HPLC assay was 
determined by assaying freshly prepared solutions of known concentration. The ability of the 
assay to quantify the compound was calculated using the following equation 2.10. 
 
Accuracy (%) = 
!"		 X 100        (2.10) 
 
A is the actual (known) concentration and T is equal to the theoretical analyte concentration. 
 
2.3.6 Chemical stability studies 
 
The chemical instability of theophylline in varying concentrations of spermine solutions was 
assessed at pH 7.4 and 9.6 (± 2) at room temperature (21 ± 2 0C). Spermine was used since 
the changes in the physicochemical properties of theophylline were the greatest when mixed 
with spermine. 1 mg mL-1 of theophylline was dissolved in 0, 50 and 100 mM of spermine 
solutions. pH adjustment was made by using HCl. The mixtures were stored in a dark 
environment away from light for 4-weeks. At 0, 1, 2, 3 and 4-week time points, 100 µL of 
each mixture was withdrawn, mixed with 900 µL of mobile phase and assayed with HPLC. 
The results were interpreted according to the percentage (%) of peak recovery and 









2.4 Results and discussion 
2.4.1 Theophylline-amine binding studies 
 
The liquid cell FT-IR trace of 0.015 mol L-1 free theophylline in water (Figure 2.1) at pH 9.6 
displayed characteristic peaks of the C=O stretching at 1600 – 1700 cm-1 (Mobaraki & 
Hemmateenejad 2011) and the C=N stretching at 1580 - 1520 cm-1 (Suydam 1963) of in great 
agreement to the previously reported FT-IR studies (Nafisi et al. 2012; Malathi 2012; Kustin 
et al. 1971). Structurally, theophylline has two carbonyl groups, C2-O11 and C6-O13 which are 
linked to the N1 atom. The C=O assignments of theophylline are complexed by the 
tautomerization of this molecule caused by the ability of the C=N of theophylline to switch 
positions between the N7 and N9 (Figure 2.2) which have distinguishable IR frequencies from 
each other (Table 2.1). This generated four C=O peaks and two C=N peaks all of which could 
























































































Figure 2.1 The liquid cell FT-IR spectrum of 0.015 mol L-1 theophylline in D2O at pH 9.6 (+ 
0.1). The insert figures show (a) the chemical structure of neutral and deprotonated 
theophylline at pH 9.6 and (b) predicted microspeciation plot of theophylline against pH. 












C2=O11  1670 1693 
C6=O12  1618 1635 




















































































Figure 2.2 Chemical structures of the two most stable tautomers of neutral and deprotonated 
theophylline (Singh 2015). 
 
 
Mixing theophylline with increasing level of amines while maintaining the pH at 9.6 led to a 
gradual increase in the absorbance of the two C=O peaks of theophylline at 1670 and 1618 
cm-1 of the N7 tautomer and a gradual decrease of the other two C=O peaks at 1693 and 1635 
cm-1 of the N9 tautomer. It is also interesting to note a gradual increase in the peak height 
ratio between the two C=N theophylline peaks (1530/1551 cm-1) when the drug was mixed 
with excess counter-ions (Figures 2.3 – 2.4). Changes in the IR spectrum of the complex 
when compared to the spectrum of the free drug provide evidence for the direct associations 
of the two molecules (Nafisi et al. 2012; Kustin et al. 1971; Malathi 2012). The FT-IR peak 
shifts indicated that the C=O and C=N of theophylline were actively involved in the non-
covalent bonding with amines. Similar observations were reported by Marta et al. (2009) 








ammonia using infrared multiphoton dissociation (IRMPD). Nafisi et al. (2012) also reported 
changes in the C=N and C=O of theophylline when complexed with cadmium (Cd2+), 
mercury (Hg2+), strontium (Sr2+) and barium (Ba2+) in an aqueous solution at physiological 
pH using FT-IR. 
 
The suppression of the N9-H tautomer of theophylline signals at 1693, 1635 and 1550 cm-1 
when excess amines were added to the mixtures evidenced that the formation of the non-
covalent interactions between theophylline and amines may have also perturbed the 
equilibrium of the tautomeric conversion process between the N7-H and N9-H tautomers of 
theophylline. Reports on the structural complexation of theophylline indicate that C6=O 
carbonyl site, which is in close proximity with the N7-H position is involved in the formation 
of intermolecular hydrogen bonds, which could explain the conformational preference of the 
N7-H tautomer over the N9-H tautomer. Stasyuk & Krygowski (2014) and Huang et al., 
(2011) previously reported the same effect of drug complex formation between metals and 





















































Figure 2.3 The liquid cell FT-IR of free theophylline (0.015 mol L-1) (dotted lines) and 
theophylline (0.015 mol L-1) mixed with 0.3 mol L-1 of (a) ethylamine and (b) 
ethylenediamine (continuous lines) from 1520-1750 cm-1 wavenumber in 0.5 M ionic 
solution pH 9.6 + 0.1. Insert figures are the proposed structures of the complexes. The dotted 
line indicates possible hydrogen bonding between the two molecules. THE-theophylline, EA 
– ethylamine, EDA – ethylenediamine. The insert figures indicate the proposed structures of 

















































Figure 2.4 The liquid cell FT-IR of free theophylline (0.015 mol L-1) (dotted lines) and 
theophylline (0.015 mol L-1) mixed with 0.3 mol L-1 of (c) spermidine and (d) spermine 
(continuous lines) from 1520-1750 cm-1 wavenumber in 0.5 M ionic solution pH 9.6 + 0.1. 
The dotted line indicates possible hydrogen bonding between the two molecules. THE – 
theophylline, SPD – spermidine, SP – spermine. The insert figures indicate the proposed 










The theophylline-amine association curves derived from the IR data were fitted with a 
Sigmoidal model (R2 > 0.97) (Figure 2.5). It was found that theophylline bound stronger to 
spermine than spermidine followed by ethylenediamine and the least with ethylamine (Table 
2.3).  
 
















pK THE-SPD = 1.93 + 0.05
R2 = 0.97 
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pK THE-EDA = 1.43 + 0.02
R2 = 0.97
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pK THE-EA = 1.32 + 0.04
R2 = 0.98 
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pK THE-SP = 1.96 + 0.04
R2 = 0.97 
 
 
Figure 2.5 Theophylline-amine associations curves at pH 9.6 ± 0.1, 21 ± 2 oC. The values 
represent n=3 + SD. The association curves were fitted with a sigmoidal regression model 
(GraphPad Prism 7) to determine the THE-amine FT-IR conditional binding constants (pKFT-
IR) which were determined at 50 % of bound theophylline. (A) Theophylline-ethylamine 
association, (B) theophylline-ethylenediamine association, (C) theophylline-spermidine 









The stronger intermolecular association between theophylline-polyamine counter-ions 
compared to theophylline-monoamine counter-ion could be due to higher hydrogen capacity 
of polyamines counter-ions (spermine = 4, spermidine = 3, ethylenediamine = 2) compared to 
monoamine (ethylamine = 1). A similar observation was reported for indomethacin (IND) 
complexed with arginine (ARG) and lysine (LYS). ARG which possessed higher hydrogen 
binding capacity (13) and was found to bind more strongly to indomethacin (pKIND-ARG = 
3.04) when compared to lysine (pKIND-LYS = 2.72) which has lower hydrogen binding 
capacity (9) (Elshaer et al. 2014).  Only one possible hydrogen bonding could be formed 
between the ionized nitrogen of theophylline at the N7 position with the hydrogen atom of the 
protonated primary amine of ethylamine. For theophylline-polyamine ion-pair complexes, the 
first hydrogen bond could occur between the negatively charged nitrogen of theophylline 
with the hydrogen atom of the ionized primary amine of the polyamines. The second 
hydrogen between the oxygen atom at the C6 position and the hydrogen atom of the charged 
secondary amine of polyamines (but second unionized primary amine for ethylenediamine) 
increased the total strength of the theophylline-polyamine ion-pair complexes (Figures 2.3-
2.4). The interaction between two theophylline with one polyamine i.e., spermine is unlikely 
to happen due to low percentage of ionization of the N1 and N2 of spermine to initiate the 
non-covalent interaction between the molecules. Spermine has 4 NH groups with the pKa of 
7.94 (N1), 8.83 (N2), 10.09 (N3) and 10.89 (N4). At pH 9.6, the percentage of ionization of 
these NH groups is as follows: 7.94% (N1), 8.83% (N2), 73% (N3) and 96 % (N4). During 
HPLC analysis, the retention time of theophylline in the biphenyl column was shortened 
when increasing concentrations of the counter-ions were mixed in the mobile phase 
indicating an increase in the interaction of ion-paired theophylline compared to the free form 
of the drug (Figure 2.6). HPLC analysis was in agreement with the binding affinity trend 








0.0065; THE-EDA, pKHPLC = 2.49 + 0.05; THE-EA = pKHPLC = 2.43 + 0.042.) (Figure 2.7). 
Nafisi et al., (2012) previously reported a stronger association of theophylline-metals 
complexes: pKCd-theophylline = 5.76, pKHg-theophylline = 5.40, pKBa-theophylline = 4.48 and pKSr-
theophylline = 4.66.  
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Figure 2.6 The HPLC chromatograms of theophylline. The stationary phase used was a 5 µm 
biphenyl 100 Å HPLC column 250 X 4.6 mm. The continuous line indicates the HPLC 
chromatogram of theophylline in a 100% water mobile phase while the dotted lines indicate 
the HPLC chromatograms of theophylline in 10 mM amine spiked water mobile phase. The 
pH of all mobile phases used was adjusted to 9.6 ± 0.2 using HCl. 
 
Note that this study was performed at physiological pH where only a small percentage of 








9.6. The reported pK values obtained from strong complexes such as divalent transition metal 
ions-EDTA complexes: pKZn-EDTA = 15.7 ± 0.3, pKNi-EDTA = 17.1 ± 0.5, pKCu-EDTA = 15.0 ± 
0.1 (Boija et al. 2014) suggested that theophylline formed a relatively weak ion-pair 
complexes with amines in solution at pH 9.6.  
 
















pK THE-EA = 2.43 + 0.042
R2 = 0.96 
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pK THE-EA = 2.79 + 0.065
R2 = 0.98 
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pK THE-EA = 2.49 + 0.05
R2 = 0.97 
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pK THE-EA = 2.81 + 0.06
R2 = 0.97 
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Figure 2.7 Theophylline-amine associations at pH 9.6 ± 0.1, 21 ± 2 oC determined by HPLC. 
The values represent n=3 + SD. The association curves were fitted with a sigmoidal 
regression model (GraphPad Prism 7) to determine the THE-amines HPLC conditional 
binding constants (pKHPLC) which were determined at 50 % of bound theophylline from the 
curves. (A) theophylline-ethylamine association, (B) theophylline-ethylenediamine 
association, (C) theophylline-spermidine association and (D) theophylline-spermine 
association. 
 
The ionisation of theophylline (pKa =8.6) is pH driven which means that a drop of pH from 








weaken the theophylline-polyamine ion-pairs and if the strength of the initial association was 
not strong enough, it would not be sufficient to influence the drug uptake when applied to the 
biological system due to rapid break down. Using theophylline pKa value and the pKFT-IR the 
strongest ion-pair complex, theophylline-spermine (1.96), the HySS calculations predicted at 
pH 7.4, ~60 % of theophylline can still ion-paired with spermine using the FT-IR analysis 
(total concentration of theophylline for IR analysis was 15 mM). However, in the clinic, the 
administration concentration of theophylline used is far lower. If we then applied the 
therapeutic concentration of theophylline (0.056 mM), the HySS calculation predicted only 
~1% of theophylline of the total theophylline could remain ion-paired to spermine in-vivo 


























































Figure 2.8 An example of HySS microspeciation plots using 1:20 ratio of theophylline-
spermine (THE-SPE) as a function of pH. Graph (a) refers to 0.015:0.3 M of theophylline-
spermine (this concentration was used in the FT-IR analysis) and graph (b) refers to 5.6 x 10-
5:1.11 x 10-3 M of theophylline-spermine mixture (this is the therapeutic concentration of 
theophylline in the plasma). The predominant species were ionised theophylline (THE-), 









We used the pKFT-IR value instead of the pKHPLC for this calculations since in the HPLC 
assay, the intermolecular interactions of the ion-pairs might be influenced by the presence of 
the stationary phase. Based on this prediction, there is a need to control the breaks down of 
this ion-pair complex when facing a rapid physiological change upon administration. To 
combat this issue, a biodegradable, non-toxic excipient (i.e., cyclodextrins) could be used to 
engineer physically stable ion-pair complex. In addition, a careful manipulation of 
formulation vehicle properties could also be employed to promote ion-pair stability. 
 
Table 2.3 Theophylline-amine conditional binding constants assayed by FT-IR (pKFT-IR) and 
HPLC (pKHPLC). Values represent n=3 + SD.*statistically significant (p<0.05) when 
compared to the pKFT-IR of THE-EA (Student’s t-test). 
 
Theophylline-amine pKFT-IR R2 pKHPLC R2 
Theophylline-ethylamine 1.32 + 0.04 0.98 2.43 + 0.042 0.96 
Theophylline-ethylenediamie 1.43 + 0.02 0.97 2.49 + 0.05 0.97 
Theophylline-spermidine 1.93 + 0.05* 0.97 2.79 + 0.065 0.98 
Theophylline-spermine 1.96 + 0.04* 0.97 2.81 + 0.06 0.97 
 
2.4.2 Log D and solubility studies 
 
Increasing the levels of amine counter-ions add to the theophylline solution significantly 
decreased the drug lipophilicity with a greater effect at pH 9.6 compared to pH 7.4 (Figure 
2.9 a,b). The decrease in the lipophilicity of the drug when mixed with excess amines 
suggested that the charges on the amines were not being totally shielded by complexation 
with theophylline. The high inherent hydrophilicity of all counter-ions (Log P ethylamine = - 
0.13; Log P ethylenediamine = - 2.04; Log P spermidine = - 0.66; Log P spermine = - 0.7) 








theophylline when formed an ion-pair with the amines. When comparing between all 
theophylline-amines mixtures studied, the magnitude of change was the greatest for 
theophylline-spermine pair followed by theophylline-spermidine then theophylline- 
ethylenediamine and the least for theophylline-ethylamine.  
 
The reversed effect was seen in the solubility studies where increasing the levels of amine 
counter-ions in the theophylline solutions led to a significant increase in the aqueous 
solubility of theophylline (Figure 2.9 c,d). Mixing theophylline with increasing levels of the 
amine counter-ions significantly increased its aqueous solubility. The magnitude of change 
was the greatest for theophylline mixed with spermine > spermidine > ethylenediamine > 
ethylamine. The results demonstrated that ion-pair properties are a function of both the drug 
and counter-ion properties and when these two elements are held together in a complex it can 
be more hydrophilic compared to the parent compound. The effects of ion-pair formation on 
solubility were more apparent at pH 9.6 compared to pH 7.4 presumable due to the greater 
proportion of ion-pairs formed at the more alkaline pH due to the theophylline’s pKa. From 
the binding studies, theophylline showed the greatest affinity towards spermine > spermidine 
> ethylenediamine > ethylamine. These results suggested that the magnitude of change in the 
physiochemical properties of theophylline was not only influenced by the lipophilicity of the 
amines but also the extent of the intermolecular theophylline-amine ion-pairs associations in 
the solution state. We expected that the change of the theophylline log D was the greatest 
when mixed with ethylenediamine due to higher lipophilicity (Log P = -2.04) of this counter-
ion compared to the other counter-ions but interestingly, our results showed that the greatest 








suggested that the strength of the ion-pair (pKFT-IR THE-SP (1.96 ± 0.04 > pKFTIR THE-EDA 

































































































































































































































Figure 2.9 The log D profiles at (a) pH 7.4 ± 0.2, (b) pH 9.6 ± 0.2 and the aqueous solubility 
at (c) pH 7.4 ± 0.2, (d) pH 9.6 ± 0.2 and of theophylline in increasing concentrations of a 
selection of amine counter-ions. Both studies were performed at 37 ± 1 oC. THE – 
theophylline, EA – ethylamine, EDA – ethylenediamine, SPD – spermidine, SP – spermine. 
Values represent means from n = 3 ± SD. Statistically significant (p < 0.05)**(p< 
0.001)(One-way ANOVA) when compared to the solubility of free theophylline. 
 
Similarly, this was previously reported by Samiei et al., (2014) when evaluating the influence 
of forming amifostine ion-pairs with different counter-ions that have different lipophilicity, 








change in the drug’s lipophilicity was not only dependent on the lipophilicity of the counter-
ions and but also the ion-pair association strength.  
 
 
2.4.3 Stability studies  
 
Theophylline displayed a well-resolved peak with retention time of 7.4 ± 0.03 min (Figure 
2.10). The standard calibration curves of theophylline (Figure 2.11) were linear (R2 > 0.99) 
which demonstrated the capacity of the developed technique to generate good results that can 



















Figure 2.10 Chromatogram of 100 ug mL-1 of theophylline in 90:03:07 









All validation parameters tested were within the recommended limits by the International 
Conference of Harmonisation (ICH, 1995) (Table 2.4). Thus, the present developed method 
was considered to be ‘fit-for-purpose’.  
 




















y = 3804 x + 3187.3
R2 = 0.9915




Figure 2.11 Intra-day and inter-day calibration curves of theophylline showing peak area as a 




It is crucial to assess the chemical stability of theophylline when mixed with the counter-ions 
to ensure any subsequent results are not influenced by degradation products. Spermine was 
used in this study because: (i) the magnitude of change in the physicochemical properties of 
theophylline was the greatest when theophylline was mixed with spermine compared to other 
counter-ions and (ii) theophylline-spermine complex will be used in a large number of excess 









Table 2.4 A summary of the assay validation data for theophylline and comparisons to the 










Linearity (R2, n = 15 calibrations, + SD) 
Peak symmetry, As, (n = 15 + SD) 
Theoritical plate number, N (n = 15 + SD) 
Limit of Detection (µg mL-1) 
Limit of Quantification (µg mL-1) 
 
 
0.996 + 0.004 
1.14 + 0.2 





< 2, Ideal As = 1 




Intra-day variability (repeatability, % CV) 







Accuracy (% + SD, n = 6) 
 
97.8 + 2.1 
 




The retention of theophylline was consistent at week 1, 2, 3 and 4 when compared to its 
retention at week 0 (Tables 2.5-2.6). A small change in the retention time of theophylline 
mixed with spermine compared to the retention of free theophylline could be attributed to the 
ion-pairing effect. The presence of new peaks in the HPLC chromatograms, which could 
indicate degradation products of the drug (Blessy et al. 2014) was not detected in any of the 
samples tested. No significant reduction of theophylline concentration in all samples 








2.6, it can be concluded that theophylline was found to be chemically stable when mixed with 
excess spermine at room temperature (21 oC + 0.1), pH 7.4 and 9.6 (+ 0.2) for up to 4 weeks.  
It can be noted in the literature that theophylline was also found to be stable in biological 
fluids (serum, saliva and plasma) up to 1 week at -20, 6 and 25 oC (Young 1981). The 
commercial product of injectable theophylline, aminophylline (1 mg mL-1) (a 2:1 complex of 
theophylline:ethylenediamine) was reported to be stable in 20 % mannitol and 0.9 % NaCl 
after 20 h at two pH ranges, 6.5 – 7.5 and 10 – 11 where it showed the highest stability at the 





























Table 2.5 Retention time (min), peak area (µV*sec) and percentage recovery of theophylline 
(1 mg mL-1/ 5.56 mmol L-1) when mixed with 50 and 100 mmol L-1 of spermine pH adjusted 
to 9.6 (+ 0.2) stored in the dark at room temperature (21 + 2 oC) at week 0, 1, 2, 3 and 4 when 









(n=3 + SD) 
Time 
(week) 
Peak area (µV*sec) 
(n=3 + SD) 
% recovery 
= (peak area 
(w1/2/3/4) /peak 
area (week 0) 
*100 
(n=3 + SD) 
0  7.40 + 0.03 0 336449 + 5070 100  
 7.43 + 0.05 1 335635 + 4115 99.75 + 0.11 
 7.44 + 0.09 2 337111 + 3090 100.20 + 0.09 
 7.45 + 0.07 3 336449 + 4115 100.19 + 0.10 
 7.44 + 0.05 4 336449 + 5070 100.73 + 0.11 
50 7.39 + 0.11 0 350045 + 5361 100 
 7.38 + 0.09 1 354541 + 5091 100.28 + 0.11 
 7.39 + 0.11 2 351187 + 4361 100.33 + 0.09 
 7.37 + 0.06 3 349089 + 4441 99.73 + 0.09 
 7.38 + 0.09 4 351172 + 5361 100.32 + 0.12 
100 7.34 + 0.10 0 361172 + 4524 100 
 7.35 + 0.07 1 362387 + 3019 100.34 + 0.06 
 7.31 + 0.10 2 362291 + 2981 100.31 + 0.05 
 7.32 + 0.09 3 364019 + 4531 100.79 + 0.08 










Table 2.6 Retention time (min), peak area (µV*sec) and percentage recovery of theophylline 
(1 mg mL-1/ 5.56 mmol L-1) when mixed with 50 and 100 mmol L-1 of spermine pH adjusted 
to 7.4 (+ 0.2) stored in the dark at room temperature (21 + 2 oC) at week 0, 1, 2, 3 and 4 when 









(n=3 + SD) 
Time 
(week) 
Peak area (µV*sec)  
(n=3 + SD) 
% recovery 
= (peak area 
(w1/2/3/4) /peak 
area (week 0) 
*100 
(n=3 + SD) 
0  7.40 + 0.03 0 336449 + 5070 100  
 7.43 + 0.05 1 335635 + 4115 99.75 + 0.11 
 7.44 + 0.09 2 337111 + 3090 100.20 + 0.09 
 7.45 + 0.11 3 336449 + 4115 100.19 + 0.10 
 7.44 + 0.04 4 336449 + 5070 100.73 + 0.11 
50 7.41 + 0.05 0 350045 + 5361 100 
 7.41 + 0.10 1 354541 + 5091 100.28 + 0.11 
 7.35 + 0.09 2 351187 + 4361 100.33 + 0.09 
 7.37 + 0.06 3 349089 + 4441 99.73 + 0.09 
 7.39 + 0.06 4 351172 + 5361 100.32 + 0.12 
100 7.38 + 0.09 0 361172 + 4524 100 
 7.39 + 0.06 1 362387 + 3019 100.34 + 0.06 
 7.38 + 0.10 2 362291 + 2981 100.31 + 0.05 
 7.35 + 0.11 3 364019 + 4531 100.79 + 0.08 











Theophylline was found to form ion-pair complexes with all the amine counter-ions tested 
when dissolved in water at pH 9.6. Spermine showed the strongest binding to theophylline 
followed by spermidine then ethylenediamine and ethylamine when assayed using FT-IR and 
HPLC. Forming polyamine ion-pairs with theophylline was shown to significantly decrease 
the drug’s lipophilicity and increase its aqueous solubility. The change in the 
physicochemical properties of the drug was found to be dependent on how strong the drug 
binds the counter-ions. However, the theophylline-polyamine ion-pairs complexes formed 
were found to be relatively weak. Upon administration, due to rapid dilution, a significant 
drop of pH as well as binding competition from other charged species to the drug, it was 
thought that the theophylline-polyamine ion-pair was likely to dissociate. It was thought that 
through complexation with cyclodextrins and manipulation of formulation vehicle, a more 
physically stable ion-pair could be formed. These sections will be discussed in the subsequent 















Chapter 3 characterized the formation of cyclodextrin complexes with theophylline-spermine 
ion-pair in water using NMR. Three types of cyclodextrins namely beta-cyclodextrin,               
2-hydroxypropyl-beta-cyclodextrin and gamma-cyclodextrin which have different 
physicochemical characteristics were used.  A continuous variation method (Job’s plot) was 
employed to establish the stoichiometry of the complexes formed. Using the 3D molecular 



















In Chapter 2, the association of theophylline-polyamine ion-pair was found weak and prone 
to dissociation. The instability of this interaction was thought could be enhanced by 
formulating with cyclodextrins. Cyclodextrins (CDs) have been found to have the ability to 
alter the physicochemical properties of the entrapped guest molecules through the formation 
of inclusion complexes (Wouessidjewe et al. 1999). CDs are cyclic (α-1,4)-linked-
oligosaccharides that display a cone-shape with a hollow tapered cavity (Horiuchi et al. 
1990). The size of the top and bottom diameters is dependent on the number of 


























6α-CD :  n = 6, R = H
β-CD :  n = 7, R = H
γ-CD :  n = 8, R = H  
 
Figure 3.1 The chemical structure and the truncated cone-shape of the three most common 










The three most common types of parent CDs are α-, β-, and γ-CDs (Table 3.1). They are 
composed of 6, 7 and 8 glycopyranose units, respectively. The exterior surface is hydrophilic 
while the central cavity is relatively hydrophobic (Horiuchi et al. 1990). CDs with ten or 
more ring member units can be theoretically synthesized, but due to their expected high 
solubility and poor complex ability, it seems unlikely that they will be used in the 
pharmaceutical industry. Whilst for CDs with fewer than six ring members, they cannot be 
formed due to steric reasons (Szejtli 1998). CDs derivatives can be formed through disruption 
of hydrogen bonding via molecular manipulation including substitution of any of the 
hydrogen bonding forming hydroxyl groups by hydrophobic moieties including methoxy and 
ethoxy which often results in modification of the CD physicochemical properties 
(Wouessidjewe et al. 1999).  
 
Table 3.1 Some characteristics of α-, β-, and γ-cyclodextrin  (Szejtli 1998) 
 α β γ 
No of glucose units 6 7 8 
Molecular weight 972 1135 1297 
Central cavity diameter (Å) 4.7 – 5.3 6.0 – 6.5 7.5 – 8.3 
Water solubility at 25 0C (g/100 mL) 14.5 1.85 23.2 
 
 
Hydroxypropyl-beta-cyclodextrin (HPβ-CD) is an example of a modified form of natural β-
CD that has an aqueous solubility of > 600 mg mL-1 while the parent β-CD only possesses an 
aqueous solubility of 1.85 mg mL-1. Through a host-guest interaction (Figure 3.2), 
complexation with CD can result in solubility enhancement of water-insoluble guests, 








masking, suppressed of unpleasant odours and controlled release (Szejtli 1998; Juluri & 
Narasimha Murthy 2014; Wouessidjewe et al. 1999). The type of guest that can be accepted 
by cyclodextrins varies from straight or branched aliphatics, aldehydes, ketones, alcohols, 
organic acids, fatty acids, aromatics, gaseous, and polar compounds such as halogens, 
oxyacids and amines (Szejtli 1998). Approximately 30 pharmaceutical formulations 
containing CDs are now available in the market worldwide of which three of them were 
marketed as intravenous, i.v. pharmaceutical products. The natural CDs are listed in the list 
of FDA as generally regarded as safe (GRAS) for use in food additive while both modified 
forms of β-CD which are HP-β-CD and SBE-β-CD are listed as inactive pharmaceutical 
ingredients in the FDA list (Stella & He 2008). This highlights the high possibility to 








Figure 3.2 A typical representation of a binary 1:1 host-guest cyclodextrin complex structure 
 
The interactions between host (H) and guest (G) are normally recognized as combinations of 
several non-covalent interactions which include ionic, dipolar, π and van der Waals 
interactions, hydrogen bonding and hydrophobic association. Even though most of the CD 








studies using ternary CD complexes which refer to the systems composed of three different 
molecular entities: drug/CD/metal ion (He et al. 2011), drug/CD/organic ion (Granero et al. 
2008; Hamai 2009), drug/CD/polymer (Loftsson et al. 2003), drug1/CD/drug2 (Higashi et al. 
2010), drug/CD1/CD2 (Jansook & Loftsson 2008) and drug/CD/liposomes (Cabeça et al. 
2011; Cirri et al. 2009). Often, the third together with CDs optimized the efficacy of a drug 
and this suggests that it could be possible to use a CD complex to stabilize the theophylline-
polyamine ion-pairs. 
 
In the case of the ternary complexes, the aqueous solubility of doxycycline was 4-fold 
increased when a metal ion, 0.5% (w/v) Mg2+ which acted as the third component was added 
to the doxycycline/HPβ-CD (1:1) mixture solution (He et al. 2011). In another study by 
Jansook & Loftsson 2008, they showed the aqueous solubility of indomethacin increased by 
30-50% when a mixture of HPβ-CD and γ-CD was added to the drug solution compared 
when just using one type of CD to complex with the drug. Organic ions were mostly used to 
improve the affinity of an ionized drug to the CD cavity. The electrostatic interaction 
between the oppositely charged drug and a counter-ion neutralized the charge of the drug 
molecule resulting in a more stable complex formation. This was previously also seen in a 
binary pyrene sulfonate (PS): γCD complex where the presence of the cationic organic 
additives neutralized the sulfonate moiety of PS which was negatively charged forming a 2-
fold stronger complex compared to the charged PS-CD complex (Hamai 2009).  
 
It was thought that CD could be employed in this present study to promote a stable 
theophylline-polyamine ion-pair complex in the solution state. This inclusion process could 
offer to shield the labile theophylline-polyamine guest complex from the degradative aqueous 








achieved, the release rate of theophylline could be controlled which could result in an 
improved uptake of the drug into the lung tissue. At pH <12, CDs do not deprotonate hence 
they will show a greater affinity towards the neutral part of the ion-pair complex than the 
ionized regions of the ion-pair (Gaidamauskas et al. 2009). The aim of this chapter was to 
characterize the supramolecular assemblies of the theophylline-spermine ion-pair complex 
with three different types of cyclodextrins: β-CD, HPβ-CD and γ-CD in aqueous at pH 9.6 
using NMR. This technique has been extensively used to characterize CD complexes in the 
literature due to its high sensitivity and ability to ascertain information about the inclusion 
complex on the atomic level (Kundu et al. 2017; Aksamija et al. 2016; Roy et al. 2016).  
 
3.2 Materials  
 
Theophylline (THE) (anhydrous, > 99%), spermine (SP) (> 99%), deuterium oxide (D2O) (D 
atom > 99%), sodium hydroxide (NaOH), hydrochloric acid (HCl), beta-cyclodextrin (β-CD), 
gamma-cyclodextrin (γ-CD) and 2-hydroxypropyl-beta-cyclodextrin (HPβ-CD) were 
purchased from Sigma-Aldrich, UK. 
 
3.3 Methods 
3.3.1 NMR measurements 
 
The FT-IR method was not used in this chapter due to the overlapping IR peaks of 
cyclodextrins with theophylline IR peaks. Therefore, NMR method was used instead. All 1H-








with a broad band inverse probe equipped with x, y and z gradients. The chemical shifts were 
referenced to the D2O signal at 4.700 ppm that was consistent in all spectra measured. For 
each 1H NMR experiment, 16 transients were collected into 65536 points over a 4010 Hz 
spectral window using 1 s relaxation delay. Prior to Fourier transformation the free induction 
decays (FIDs) were zero filled with 63 536 points and apodized by multiplication with an 
exponential decay to 1 Hz line broadening. A rotational overhauser enhancement experiment 
(ROESY) for detection of intermolecular nuclear overhauser effects (NOEs) between β-CD 
and the theophylline-spermine ion-pair (assuming a 1:1 THE-SP complex was formed when 
theophylline and spermine were mixed at 1:20 drug-spermine molar ratio) was conducted for 
the inclusion complex (1:1 molar ratio of β-CD:[THE-SP]) at 298 K. The 2D ROESY 
spectrum was collected with mixing time of 300 ms under the spin lock condition. 
 
3.3.2 Theophylline-spermine binding 
 
The NMR conditional binding constant (pKNMR) of theophylline-spermine was assessed by 
titrating increasing concentration of spermine into the theophylline solutions prepared in 
D2O. The concentration of theophylline was fixed at 5 mM whilst the concentration of 
spermine varied from 0 – 100 mM. The pH of all mixtures was adjusted to 9.6 using HCl. 
Changes in the proton signals of theophylline upon mixing with excess spermine were used 
to establish the theophylline-spermine association curve. The percentage of theophylline 
bound vs –log[spermine]free were plotted and fitted with a regression model (GraphPad 
Prism7) to determine the pKNMR of theophylline-amines complexes in D2O. Results were 









3.3.3 Job’s plot  
The continuous variation method employed was in accordance with the previous studies (Roy 
et al. 2016; Korytkowska-Wałach et al. 2017). A series of solutions containing mixtures of β-
CD/HPβCD/γ-CD with THE-spermine ion-pair at different CD-ion-pair molar ratios were 
measured. The total concentration of the interacting species [CD + (THE-SP)] in the 
solutions was kept constant at 5 mM. The molar fraction (r) of [CD]/[CD mixture] varied in 
the range of 0.1 – 0.9. The pH of all mixtures was kept at 9.6 ± 0.1. Any pH adjustment was 




3.3.4 Molecular docking studies 
	
	
The atomic coordinates for theophylline and spermine were from the PubChem database 
(Bolton et al, 2011). For beta-cyclodextrin, the atomic coordinates were accessed through the 
Crystallography Open Database and taken from the dataset provided by Pop et al. (2002). 
Modelling of the ternary inclusion complex was carried out using HyperchemTM and the 
structure was optimised using Polak-Ribiere conjugate gradient minimisation of the potential 
energy to an rms gradient of 0.001 kcal/(mol.Å). Images were generated using Discovery 












3.4 Results and discussion 
 
The 1H-NMR spectrum of theophylline in D2O, pH 9.6 revealed three singlet proton peaks 
(Figure 3.3). The peak at 7.579 ppm was assigned to the C8-H of theophylline whilst the 
peaks at 3.303 and 3.489 ppm were assigned to the C10- and C12-H of theophylline which was 
in line with the literature (Terekhova et al. 2007). The hydrogen at N7-H of theophylline was 
not visible in the spectrum due to deprotonation at pH 9.6. For spermine molecule, a singlet 
at 1.821 ppm was assigned to the C-H2 of spermine whilst the peaks at 1.569 ppm and at 
2.882 ppm were assigned to the C-H1 and C-H3 of spermine, respectively. The N-H 
hydrogens of spermine were not detectable due to the proton exchange with the D2O 
molecule. Addition of increasing level of spermine to the theophylline solution while 
maintaining the pH at 9.6 caused upfield shifts of theophylline protons which could be 
attributed to the ion-pairing effect (Figure 3.3). Of the three proton signals of theophylline, 
the proton at C8-H was mostly affected upon forming ion-pair with spermine (Table 3.2). 
This might be due to its position. It was in close proximity to the N7 of theophylline which 
was thought to be actively in contact with the spermine molecule through hydrogen bonding 
(Figure 3.3). Change in the chemical shift of the C8-H of theophylline when mixed with 
increasing level of spermine was used to establish the theophylline-spermine association 
curve fitted with a Sigmoidal model (R2 > 0.99) (Figure 3.4). From this model, the pKNMR of 

































































































































Figure 3.3 (a) The 1H-NMR spectra of 0.005 M theophylline (bottom graph), 0.1 M 
spermine (middle graph) and theophylline-spermine 0.005:0.1 M mixture (top graph) in D2O 
pH 9.6 + 0.1 and (b) the proposed chemical structure of the ion-pair complex. Dotted lines 








The shifts of the hydrogen signals of spermine when mixed with theophylline at 20:1 
spermine:theophylline molar ratio were also affected but this change was small, which could 
be due to the broad multiple signals of the spermine and the free unbound spermine in the 
system. Of three proton signals of spermine, H-3 of spermine showed the greatest change 
compared to the H-1 and H-2 of spermine, this proton was adjacent to the hydrogens of the 
ionized primary and secondary amines of spermine which were postulated to form a link with 
theophylline through hydrogen bonding. 
 
 
Table 3.2 Chemical shifts of free theophylline (5 mM), spermine (100 mM) and 









  Free  Complex 
(1:20) 
Complex-Free 
Theophylline C8-H 7.589 7.543 - 0.046 
 C10-H 3.303 3.297 - 0.006 
 C12-H 3.489 3.483 - 0.006 
Spermine H-1 1.821 1.822 - 0.001 
 H-2 1.569 1.563 - 0.003 





















































Figure 3.4 (A) The change of C8-H of theophylline when mixed with increasing 
concentration of spermine in D2O pH 9.6 ± 0.1 and (b) theophylline-spermine association 
curve. The values represent n=3 + SD. Error bars are too small to be seen. The association 
curve was fitted with a Sigmoidal regression model (GraphPad Prism 7) to determine the 
THE-spermine NMR conditional binding constants (pKNMR) which were determined at 50 % 
of bound theophylline. 
 
 
Figure 3.5 showed the 1H-NMR spectra of 5 mM β-CD, HP-β-CD and γ-cyclodextrin in D2O 
pH 9.6. The peak assignments (Table 3.3) were in line with the previous studies (Wei et al. 
2017; Weiss-Errico & O’Shea 2017). A continuous variation method known as Job’s plot 
was used to establish the stoichiometry of the host-guest complexes using NMR. Job’s plots 
were generated by plotting the change in the chemical shift of H-3 of cyclodextrins 
(∆ppm*[CD](mM)) against varying molar fractions (r) of [CD/CD:(THE:SP) complex] 
which was set between 0.1 – 0.9 at a constant total concentration of 5 mM. The stoichiometry 
of the complexes was found to be 1:1 as the maximum plots were obtained at r = 0.5 (Figure 
3.6) (Roy et al. 2016; Korytkowska-Wałach et al. 2017).  Note that r = 0.5 means that CD-







































β-CD: n = 7, R = H
HPβ-CD: n = 7, R = CH2CH2(OH)CH3





Figure 3.5 (a) The 1H NMR spectum of 0.005M beta-cyclodextrin (bottom graph), 0.005 M 
hydroxypropyl-beta-cyclodextrin (middle graph) and 0.005 M gamma-cyclodextrin (top 
graph) in D2O pH 9.6 + 0.1 and (b) the chemical structure of the respective CDs. * asterisk 
highlights the D2O signal. 
 
 
The addition of theophylline-spermine ion-pair complex to the CD solutions induced upfield 
shifts in all of the hydrogens signals of all three CDs used (Table 3.3) which suggested that a 
host-guest complex was formed (Kundu et al. 2017). Upon complexation, the hydrogens of β-
CD showed the greatest signal shifts followed by the hydrogens of γ-CD then HP-β-CD. This 
suggested stronger intermolecular interactions between theophylline-spermine ion-pair with 
β-CD > γ-CD > HP-β-CD (Table 3.4). In order to form a well fitted host-guest complex, the 
size of CD cavity must be compatible enough (Szejtli 1998). In addition, it is well established 
that the hydrophobic interaction plays a major role in stabilizing the cyclodextrin complexes 








must possess an ideal hydrophobicity for a stable CD complex to be formed. The effects of 
size and polarity the guest molecules on the stability of the CD complexes have been 
observed previously. In per our case, as described in Chapter 2, that mixing theophylline with 
an excess spermine significantly increased its hydrophilicity. This could explain the relatively 
small shifts all CD protons regardless of the type used when mixed with the ion-pair which 
suggested the formation of relatively weak CD:[THE:SP] complexes. As for HP-β-CD, the 
bulky hydroxypropyl groups surrounding the CD cavity might provide an additional 
hindrance for the formation of a stable inclusion complex due to steric hindrance. In addition, 
the presence of bound spermine to theophylline increased the overall size of the guest 
molecule which could influence the complex formation. Overall, the magnitude of change of 
the hydrogens of β-CD molecule which are located in the inner cavity was the greatest for H-
3 (-0.052 ppm) followed H-5 (-0.046 ppm) compared to the very small changes observed 
with H-6 (-0.03 ppm) which is located on the cavity rim at the narrow end of the molecule, 
upon mixing with the theophylline-spermine ion-pair. Signal changes were also observed for 
the hydrogens positioned on the outer cavity of β-CD: H-1= -0.036 ppm, H-2 = -0.035 ppm, 
H-4 = -0.038 ppm, but the changes were less than those in the inner cavity. The proton 
signals of theophylline and spermine were also affected where the hydrogen on the imidazole 
ring of the theophylline molecule at the C8 position demonstrated the largest shift (- 0.038 
ppm) followed by the hydrogens at C12 (- 0.030 ppm) and at C10 (- 0.028 ppm) (Table 3.4), 
indicating the penetration of the theophylline molecule into the β-CD cavity (Korytkowska-
Wałach et al. 2017). This also suggested that theophylline entered the β-CD cavity through 
the imidazole ring from the wider end of the β-CD molecule. Spermine could exist in a 
mixture form of bound and free unbound to the drug molecule in the complex solutions 
which made the interpretation on the shifts of its signals complexed (Table 3.5).  Identical 































































Figure 3.6 Job’s plots of (A) γ-cyclodextrin, (B) β-cyclodextrin and (C) HP-β-cyclodextrin 
complexed with theophylline-spermine (1:20 molar ratio) at pH 9.6 ± 0.1 using the chemical 



































Figure 3.7 The 1H-NMR spectra of β-CD-THE-SP (bottom graph), HP-β-CD-THE-SP 
(middle graph) and γ-CD-THE-SP (top graph) (CD-THE-SP molar ratio; 0.005:0.005:0.1 M) 
















Table 3.3 The chemical shifts, ∂ (ppm) of the free cyclodextrins and when formed the 
complex i.e., cyclodextrin-theophylline-spermine complex (1:1:20 molar ratio) in D2O pH 









  Free CD Complex Complex-Free 
CD 
HP- β-CD H-1 5.198 5.177 - 0.021 
 H-2 3.666 3.646 - 0.020 
 H-3 3.971 3.949 - 0.022 
 H-4 3.576 3.557 - 0.019 
 H-5 3.816 3.795 - 0.021 
 H-6 3.816 3.799 - 0.017 
 H-Me 1.103 1.084 - 0.019 
β -CD H-1 5.014 4.978 - 0.036 
 H-2 3.612 3.577 - 0.035 
 H-3 3.933 3.881 - 0.052 
 H-4 3.553 3.515 - 0.038 
 H-5 3.824 3.778 - 0.046 
 H-6 3.857 3.817 - 0.030 
γ -CD H-1 5.056 5.015 - 0.041 
 H-2 3.619 3.577 - 0.042 
 H-3 3.906 3.862 - 0.044 
 H-4 3.560 3.519 - 0.041 
 H-5 3.820 3.777 - 0.043 












Table 3.4 The chemical shifts, ∂ (ppm) of the ion-paired theophylline and when formed the 
complex i.e., cyclodextrin-theophylline-spermine complex (1:1:20 molar ratio)  in D2O pH 









  [THE-SP] CD Complex Complex – 
[THE-SP] 
HP-B-CD-THE-SP C8-H 7.543 7.534 - 0.009 
 C10-H 3.297 3.287 - 0.010 
 C12-H 3.483 3.472 - 0.011 
B-CD-THE-SP C8-H 7.543 7.505 - 0.038 
 C10-H 3.297 3.267 - 0.030 
 C12-H 3.483 3.451 - 0.032 
G-CD-THE-SP C8-H 7.543 7.533 - 0.010 
 C10-H 3.297 3.285 - 0.012 
 C12-H 3.483 3.468 - 0.015 
 
 
Table 3.5 The chemical shifts, ∂ (ppm) of the ion-paired spermine and when formed the 
complex i.e., cyclodextrin-theophylline-spermine complex (1:1:20 molar ratio) in D2O pH 













HP-B-CD-THE-SP H-1 1.821 1.816 - 0.005 
 H-2 1.569 1.553 - 0.016 
 H-3 2.882 2.867 - 0.015 
B-CD-THE-SP H-1 1.821 1.806 - 0.015 








 H-3 2.882 2.842 - 0.040 
G-CD-THE-SP H-1 1.821 1.827 - 0.006 
 H-2 1.569 1.551 - 0.018 
 H-3 2.882 2.864 - 0.018 
 
 
Using the 3D molecular modelling technique, it was calculated that ~10% of the volume of 
the spermine, and ~10% of the volume of the theophylline were inserted into the β-CD cavity 
(Figure 3.8). In this (energy minimised) model, the theophylline-spermine N7....H distance 
was 2.2 Å. The theophylline and spermine cannot penetrated the β-CD cavity to any greater 
depth, because the sum of their cross-sectional areas (~28 Å2 and 25 Å2, respectively) 
exceeded the cross-sectional area of the cavity (42 Å2). The result from the 2D ROESY did 
not show any signals corresponding to the formation of the intermolecular association 
between CD and the ion-pair which could be due to its limited sensitivity to detect the 


























Figure 3.8 The proposed structure of a 1:1 βCD-[THE-SP] complex in water at pH 9.6. In 
pictures A and B, blue=nitrogen, red=oxygen, white=hydrogen, grey=carbon. In picture C, 














H-1,-2,-3 of spermineC-10 & 12 of theophylline





































Figure 3.9 2D ROESY spectrum of 1:1 β-CD/[THE-SP] complex in D2O pH 9.6. Insert 
figures show the ROESY signals assigned to the spermine-spermine and CD-CD 






The formation of CD-THE-SP complexes in aqueous was confirmed when assessed using 
NMR where β-CD was found to have the strongest affinity towards the ion-pair followed by 
γ-CD then HPβ-CD. The stoichiometry of the complexes was 1:1 as evidenced from the Job’s 
plot studies. It was hypothesized that through encapsulation with CDs, an improved physical 
stability of the ion-pair can be achieved hence the uptake of the drug into the lung tissue 
could be optimized. This section will be covered in the subsequent chapter of this thesis.  
 CHAPTER 4 
EFFECT OF CO-SOLVENT ON THE COMPLEX STABILITY 
AND pH-INDUCED DISSOCIATION OF THEOPHYLLINE-




This chapter assessed the effect of co-solvent on the theophylline-spermine association.The 
conditional binding constant of theophylline-spermine (pKTHE-SP) was measured in different 
mixed solvents: 5%, 10 % ethanol-D2O and 30%, 70% propylene glycol-D2O using FT-IR at 
pH 9.6 ± 0.1 and compared to the pKTHE-SP in D2O. The pH-induced dissociation of the ion-
pair with and without the presence of cyclodextrin was studied using FT-IR 
spectrophotometer to trace the break down of the ion-pair. The dissociation study was 
designed to simulate the ion-pair dissociation induced by the immediate drop of pH to 7.4 



















Docking the theophylline-spermine ion-pair in a CD complex could enhance its stability, but 
as docking was not optimal as shown in Chapter 3, it was felt that an alternative stability 
strategy should be sought. It is known that the properties of a solvent greatly influenced the 
extent of the solute-solvent and solute-solute interactions exist in the pharmaceutical systems 
(Takjoo & Mague 2017; Yang et al. 2017; Chakraborty et al. 2017; Bartyzel 2017). The 
change in these interactions if ideal, can promote ion-pair stability. The effect of solvent 
properties on the metal-ligand complexes stability has been studied previously. Mui and 
McBryde (1974) reported an increased in the stability constant of metal complexes (nickel 
(II), zinc (II) and manganese (II)) with ethylenediamine and glycine in mixed aqueous 
solution with increasing composition of the co-solvent. Higher stability of the complexes 
were found in a less polar mixing co-solvent: dioxane > acetonitrile > methanol > water. This 
previous work postulated that the increased complex stability was due to the displacement of 
water molecules, which resulted in smaller solvating capacity, hence a more stable complex 
was formed. In an organic-rich mixed solvent, the solvent ‘charge-shielding’ effect is reduced 
due to the decrease of the dielectric constant (ε) which increases the long-range electrostatic 
interactions (Wang & Cole 1996). A similar observation was reported by Felmy et al., (2017) 
who studied the effect of mixed solvents on the complexation thermodynamics of Eu (III) 
with 2-hydroxyisobutyric acid (HIBA) and 2-aminoisobutyric acid (AIBA) in mixed 
methanol (MeOH)-water and N,N-dimethylformamide (DMF)-water solvents. A greater 
complex stability was obtained with increasing percentage of organic solvent in the mixing 
solvent. In another study conducted by Adam et al., (2016) it was shown that the complex 
formation constant (K) of the charge transfer complex between anticholinergic drug 








104 M-1) compared when the complex was prepared in MeCN (ε= 37.5; K = 42 x 104 M-1). A 
similar effect was reported by Asim et al., (2014) when the group studied exciplexes of 1-
cyanonaphthalene with hexamethylbenzene in solvents with different polarity. These studies 
suggested that an organic solvent can modify the autoprotolysis constant of the solvent (pKs) 
and the pKa of the ligand, which can influence the complex stability constants. The changes 
in the solvent equilibria were governed by several properties of the solvent those include the 
dielectric constant of the solvent, the extent of hydrogen bonding, solvent size, and the 
preferential solvation of ions in solution. This strategy could also be useful to enhance the 
physical stability of the theophylline-spermine ion-pair. The dissociation of therapeutic ion-
pairs is inevitable when enter the biological systems due to the effect of dilution, which 
exposes the liable complex to binding competition with the charge-bearing groups. 
Encapsulating the theophylline-spermine in the cyclodextrin cavity and using excess 
spermine to force the drug to bind to the counter-ion, it was thought that through careful 
manipulation of formulation vehicle properties, a more stable theophylline-polyamine ionic 
complex could be engineered. If this could be achieved, the dissociation rate of the ion-pair 
could be slowed down. The aims of this chapter were to (i) investigate the impact of co-
solvents i.e., propylene glycol (PG) and ethanol (EtOH) on the association of theophylline-
spermine ion-pair and (ii) to assess the pH-induced dissociation of the ion-pair in different 
mixed solvents formulation vehicles by using FT-IR. The dissociation profile of the 
complexed ion-pair with cyclodextrin will be compared with the non-complexed ion-pair to 
assess the ability of cyclodextrin to control the break down of the ion-pair in response to the 
change of pH. The theophylline-spermine association was determined in different EtOH-D2O 
and PG-D2O mixtures at a constant pH 9.6 ± 0.1 using FT-IR.  PG and EtOH are commonly 
used oral and intravenous formulation to improve the solubility of poorly soluble drugs 








excipients safe for use in medication and cosmetics. The European Medicines Agency placed 
ethanol in class 3 solvents i.e., solvents with low toxic potential, whilst propylene glycol, 




Theophylline (THE) (anhydrous, >99%), spermine (SP) (> 99%), beta-cyclodexetrin (ß-CD), 
deuterium oxide (D2O) (>99% D), propylene glycol (USP standard), deuturated ethanol 
(EtOH-OD) (>99.5% D), sodium hydroxide (NaOH), hydrochloric acid (HCl), sodium 




4.3.1 Theophylline-spermine binding studies 
 
The infrared (IR) conditional binding constant (pKFT-IR) of theophylline-spermine (0.015:0.3 
mol L-1) were assessed using a universal liquid cell system (Omni-Cell, Specac Ltd, UK) 
fitted with CaF2 windows and a 0.025 mm Mylar spacer (Specac Ltd, UK) was used for the 
absorbance measurements. The pKFT-IR of theophylline-spermine was determined in EtOH-
D2O (5% and 10% v/v) and PG-D2O (30% and 70% v/v) mixed solvents to assess the effect 
of co-solvents on the ion-pair association. The ethanol and PG concentrations tested were 
within the accepted limit by EMA. The absorbance spectra were recorded within the range of 








necessary to keep a constant ionic strength (0.5 M) in all mixtures. All spectra were 
subtracted with the spectra of the blank solutions and baseline corrected. The blank solutions 
refer to the exact compositions of the test solutions in the absence of theophylline. Changes 
in the peak absorbance ratio at ca. 1530/1551 cm-1 were calculated where the peak at ca. 1551 
cm-1 was assigned to the uncomplexed theophylline and the peak at ca. 1530 cm-1 as the 
complexed theophylline. The change in the ratio of these peaks was used to determine the 
percentage of theophylline bound as a function of spermine concentration. The percentage of 
theophylline bound vs –log[spermine]free were plotted and fitted with a regression model 
(GraphPad Prism7) to determine the FT-IR conditional binding constant (pKFT-IR) of 
theophylline-spermine ion-pair. All spectra were recorded using a Spectrum One 
spectrometer (Perkin Elmer Ltd, UK) and spectral analysis was performed with Spectrum 
version 10 software (Perkin Elmer Ltd, UK). The resolution was set at 4 cm-1 and 12 scans 
were performed for each measurement. Experiments were repeated in triplicate and the 
results were presented as mean + SD. 
 
4.3.2 pH-induced dissociation studies 
 
The test solutions consisted of 0.015 mol L-1 theophylline, 0.015 mol L-1 cyclodextrin and 0.3 
mol L-1 spermine were made up in D2O, EtOH-D2O and PG-D2O, pH adjusted to 9.6 ± 0.2 
using HCl.  To simulate the immediate change in the pH upon administration, the pH of the 
test solutions was adjusted to pH 7.4 ± 0.2 just prior to the spectral measurement using a pre-
determined volume of HCl (5 M). The samples were then mounted in a universal 
transmission cell system (Omni-Cell, Specac Ltd., UK) fitted with CaF2 windows and a 0.025 








(Perkin Elmer Ltd., UK). A total of 25 ± 5 s elapsed before the first scan was taken (time 
needed to mount the cell onto the spectrometer). The monitoring of the C=N and C=O peaks 
of theophylline was carried out for a continuous 20 min using TimeBase™ software (Perkin 
Elmer Ltd., UK). The pH was monitored throughout the process. The FT-IR method was 
used because it is sensitive to detect ion-pair dissociation unlike UV or fluorescence analysis. 
NMR analysis was less sensitive that FTIR. 
 
4.4 Results and discussion 
4.4.1 Binding studies 
 
Figure 4.1 demonstrated the IR spectra of free theophylline (0.015 mol L-1) in different 
aqueous organic mixed solvents at pH 9.6. It appeared that the four carbonyl signals within 
the range of 1700 – 1500 cm-1 of theophylline were sensitive to the change in the polarity of 
the medium used whilst the C=N peaks at ca. 1551 and 1530 cm-1 of theophylline remained 
unaltered (Table 4.1). It should be noted that, as described in Chapter 2, theophylline forms 
dimer in solution. The self-association of theophylline could occur between the H on the C8 
position with the O at the C6 position in aqueous at pH 9.6. A larger theophylline C=O peaks 
shift was seen when theophylline was dissolved in the PG-D2O mixtures compared to the 
EtOH-D2O mixtures. The shift of the peaks to higher wavenumbers suggested a weaker drug-
solvent interaction resulted from a stronger drug-drug interaction. This suggested, that 
decreasing the overall medium polarity of the mixed solvent system increased the degree of 








rank the formulation vehicles in terms of polarity: D2O = 78; 5% (v/v) EtOH-D2O = 75.35; 














30 %  PGA











































Figure 4.1 The liquid cell FT-IR spectra of 0.015 mol L-1 theophylline in different 
formulation vehicles at pH 9.6 + 0.1, 21 ± 2 oC. (A) in 30 and 70 % (v/v) of propylene glycol 









Table 4.1 Experimental wavenumbers (cm-1) of 0.015 mol L-1 theophylline in different 

















































The addition of increasing concentrations of spermine to the theophylline solutions caused a 
gradual increase in the absorbance of the two C=O peaks of theophylline at ca. 1670 cm-1 and 
1618 cm-1 and a gradual decrease of the other two C=O peaks at ca. 1696 and 1637 cm-1. This 
was in agreement with the results in Chapter 2. In addition, the intensity of the C=N peak of 
the drug at ca. 1530 cm-1 which was assigned to the complexed theophylline increased 
gradually whilst the other C=N peak at ca. 1551 cm-1 that was assigned as the uncomplexed 
theophylline gradually decreased with an increase in the spermine concentrations. The FTIR 
peak shifts of the theophylline C=O and C=N were attributed to the ion-pairing effect. These 
trends of changes were seen in all of the mixed solvent systems studied (Figures 4.2-4.3).  
The theophylline-spermine association curves derived from the FT-IR data were fitted with a 
Sigmodial model (R2 > 0.95) (Figure 4.4). The pKFT-IR of theophylline-spermine obtained in 
the ethanol and PG solvent systems were as follows (Table 4.2): theophylline-spermine 








0.053; 5% EtOH-D2O = 2.04 ± 0.05.; D2O = 1.96 ± 0.04. However, there was not statistically 













































Figure 4.2 The liquid cell FT-IR of 0.015 M theophylline and 0.015 mol L-1 theophylline 
mixed with 0.3 mol L-1 spermine at pH 9.6 + 0.1 in (A) 30/70 (v/v) propylene glycol/D2O and 





















































Figure 4.3 The liquid cell FT-IR of 0.015 mol L-1 theophylline and 0.015 M theophylline 
mixed with 0.3 mol L-1 spermine at pH 9.6 + 0.1 in different solvent systems (A) 5/95 (v/v) 



























pK THE-SP = 2.05 + 0.057
R2 = 0.97 

















pK THE-SP = 2.04 + 0.05
R2 = 0.96 

















pK THE-SP = 2.11 + 0.045
R2 = 0.97 

















pK THE-SP = 2.05 + 0.053
R2 = 0.95 
 
 
Figure 4.4 Theophylline-spermine binding association assayed by FT-IR at pH 9.6 + 0.1, 21 
± 2 oC in different co-solvents systems: (A) 30/70 (v/v) propylene glycol/D2O, (B) 70/30 
(v/v) propylene glycol/D2O, (C) 5/95 (v/v) ethanol/D2O and (D) 10/90 (v/v) ethanol/D2O. 
Values represent means from n=3 + SD. The association curves were fitted with a sigmoidal 
regression model (GraphPad Prism 7) to determine the THE-spermine association constant 














Table 4.2 The conditional FT-IR theophylline-spermine binding constants (pKFT-IR) in 
different solvent systems at pH 9.6 + 0.2. Values represent means from n=3 + SD. 
 
Solvent system pKFT-IR  R2 
D2O 
30/70 (v/v) propylene glycol/D2O 
1.96 ± 0.04 
2.05 + 0.057 
0.97 
0.97 
70/30 (v/v) propylene glycol/D2O 2.11 + 0.045 0.97 
5/95 (v/v) ethanol/ D2O 2.04 + 0.05 0.96 
10/90 (v/v) ethanol/ D2O 2.05 + 0.053 0.95 
 
 
4.4.2 Dissociation studies 
 
Dissociation studies were carried out to assess the pH-induced dissociation of the ion-pair. 
An immediate change of pH from pH 9.6 to pH 7.4 was achieved by adding a known amount 
of concentrated HCl. The mixture was then mixed and analyzed using FT-IR. The change of 
pH over time was monitored closely by inserting a pH checker into the test solutions. In order 
to understand the FT-IR dissociation, the IR spectra of the theophylline-spermine ion-pair 
(1:20) was prepared at different pHs (6, 8, 8.5, 9 and 10) (Figure 4.5). Using the spectra of 
the theophylline-spermine ion-pair at different pHs, the peaks (in D2O) of at ca. 1550 cm-1, 
1673 cm-1 and 1617 cm-1 were assigned to the dissociated ion-pair whilst peaks at ca. 1530 
cm-1, 1619 cm-1 and 1673 cm-1 were assigned to the associated ion-pair. The FT-IR spectra at 
pH 9.6 were the associated ion-pair at t=0. Changing the pH to 7.4 upon addition of the HCl 
resulted in the significant suppression of all the ion-paired theophylline peaks regardless of 
the formulations tested (Figures 4.6-4.7) which suggested the ion-pair broke down almost 








cyclodextrin in a co-solvent had a minimal impact on controlling the dissociation of the 















































Figure 4.5 The liquid FT-IR spectra of theophylline-spermine (15:300 mM) in water at 
different pH. Note that a higher percentage of ionized theophylline reflects a greater 
possibility of theophylline to form ion-pair with spermine. 
 
 
The sudden drop in the pH of the mixture caused solvent rearrangements. This could 
significantly perturb the thermodynamic stability of the ion-pair complex which resulted in a 
rapid break down of the complex. Identical observations have been reported previously (Pey 
2014; Ballard & Dellago 2012). Unfortunately, the process between adjusting the pH until the 
test solutions could be assured in the static FT-IR cell to start the measurement took ca. 25 
sec which was thought to be longer than the time for the ion-pair to reach the lung tissue from 
the site of infusion. However, the ion-paired peaks at ca. 1618 cm-1 and 1530 cm-1 were still 








theophylline even at pH 7.4 (as predicted in Chapter 2). The appearance of multiple peaks 
within the C=N region at 1520 – 1550 cm-1 suggested that after ion-pair dissociation a small 
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Figure 4.6 The liquid FTIR of theophylline-spermine (15:300 mM) in (A) D2O and (B) 10 % 
























































Figure 4.7 The liquid FTIR of (A) theophylline-spermine (15:300 mM)  and (B) beta-
cyclodextrin-theophylline-spermine (15:15:300 mM) in 70% PG-D2O measured continuously 











Theophylline was found to bind more strongly to spermine in the mixed solvent with the 
presence of increasing concentrations of the organic solvent. Regardless of the formulation 
vehicles tested, theophylline-spermine ion-pair dissociated almost immediately when the pH 
of the test solutions was dropped to 7.4. However, a small portion of the theophylline peaks 
at ca. 1530 and 1618 cm-1 was still able to be detected even at pH 7.4 suggested that the small 













 CHAPTER 5 
IN-VITRO CELL BIOCOMPATIBILITY AND CELLULAR 
UPTAKE OF THEOPHYLLINE-POLYAMINE COMPLEXES 




The data reported in this Chapter demonstrated that free theophylline, spermine, cyclodextrin 
and the theophylline-spermine ion-pair complex formulated with cyclodextrin, were all 
biocompatible with  human lung epithelial (A549) cells. The formation of a theophylline-
spermine ion-pair enhanced theophylline uptake into the A549 cells, time-dependent 
accumulation of the drug was not observed due to the theophylline efflux by P-gp. 
Formulating the ion-pair with cyclodextrins increased the total accumulation of theophylline 
over time and provided a sustained transport enhancement, which suggested that association 




















In Chapter 4 the theophylline-spermine ion-pair, formulated at pH 9.6, showed rapid 
dissociation when the pH of the solution was dropped to 7.4 (i.e., physiological conditions). 
A similar outcome was observed even when the ion-pair was mixed with cyclodextrins in a 
co-solvent, which suggested if an ion-pair complex was formed the pH change would drive 
dissociation. It was not possible to measure the speed of complex dissociation hence in this 
chapter, we further investigated if the remaining theophylline paired to the spermine could 
have an impact on the drug uptake in lung epithelial using a functional assay in order to 
assess if formulating ion-pairs with cyclodextrins can alter the drug transport into the cells. 
 
The ability of a molecule to permeate into cells depends on many factors, but one of the most 
important factors is the molecule’s physicochemical properties e.g., size, lipophilicity and 
hydrogen bond capacity (Kell & Oliver 2014). A small molecule with moderate 
hydrophilicity can passively diffuse through the cell membrane whilst polar molecules often 
utilize the membrane transporters, which facilitate their membrane penetration (Muth et al. 
2013). Cell transport facilitated by transporters is dependent on the specific substrate-
transporter binding. Since the expression of the transporters varies according to the cell type, 
this can enable drug targeting (Scott et al. 2017). The most important transporter for the 
theophylline spermine ion-pair studied in this thesis is the active polyamine transport system 
(PTS). The PTS regulates the intracellular level of polyamines, which are essential for cell 
growth, division and differentiation (Guminski et al. 2009; Palmer & Wallace 2010). In 
healthy cells, the pulmonary tissue appears to express high levels of polyamine transporters, 
observed as a consequence of their ability to accumulate higher polyamine compared to cells 








might offer a means to target drug delivery to the lung. The PTS has been identified and 
functionally characterized in lung alveolar type 1 and type 2 cells, Clara cells (Nemery 1987; 
Wyatt 1988; Dinsdale 1991; Kameji 1984) and the pulmonary arterial endothelial cells 
(Sokol et al. 1992). From the published studies, it appears that the PTS is a saturable, carrier-
mediated, time, temperature, pH, energy and concentration-dependent transporter system 
(Seiler and Dezeure, 1990; Cullis et al. 1999; Dot et al. 2000; Raksajit et al. 2009; 
Kruczynski et al. 2009; Kuramoto et al. 2003).  
 
The ability of PTS to target the delivery of molecules to cancer cells, which overexpressed 
the PTS has been previously investigated (Palmer & Wallace 2010), but the use of this 
transporter to target lung cells has only been tested using nanomaterials. Li et al., (2017) 
investigated the active delivery of doxorubicin (DOX), a chemotherapeutic agent loaded in 
spermidine-modified nanoparticles (SPD-DOX-NPs) in human lung carcinoma (A549) cells. 
Spermidine is an endogenous polyamine with a moderate chain length that is protonated at 
physiological pH. In Li et al’s study, cells treated with a spermine coat (SPD-DOX-NPs) 
showed the brightest fluorescence, which indicated a higher cell uptake of DOX-loaded NPs 
compared to free DOX and DOX-NPs, without the polyamine. Results from flow cytometry 
showed a significant increase of SPD-DOX-NPs cell uptake compared to free DOX (p<0.01) 
and DOX-NPs (p<0.05) and this data suggested that the drug was actively taken up into the 
cell via specific SPD-PTS binding after 1 h of incubation. The SPD-DOX-NPs exhibited 
spermidine concentration-induced toxicity where the cytotoxicity was 1.6-fold and 2.0-fold 
greater compared to SPD-free and free DOX, respectively when the spermidine concentration 
was at the highest. Barret et al., (2008) assessed the targeted delivery of polyamine-
containing drug in cancer cells using F14512, which is a toposimomerase II inhibitor. In the 








ovary (CHO) cells compared when tested in a mutant cell line (CHO-MG) with a reduced 
PTS activity. The IC50 values for F14512 were 0.12 and 8.7 umol L-1 in CHO and CHO-MG 
cells suggested that PTS facilitated the internalization of the drug in the cells in the presence 
of spermine moiety.  
 
Most of the studies in the literature generally reported an enhanced permeability of drugs 
when forming ion-pairs due to an increase in drug’s lipophilicity, which allow a higher 
passive diffusion of the molecule across the biological barriers (Samiei et al. 2014; 
Tantishaiyakul et al. 2004; Liu et al. 2011).  However, a study by Paugam and Smith (1993) 
proved that this strategy could also be used to improve the molecule uptake through an active 
transport. Their results demonstrated an active transport of uridine paired with phenylboronic 
acid across an organic liquid membrane through a F- ion channel. The major concern when 
using the ion-pairing approach in drug delivery is the instability of the ion-pair association, 
which can result in a rapid dissociation, if a labile ion-pair is formed. This has been 
previously studied by Zhao et al., (2017) when assessing the skin permeation of bisoprolol 
ion-paired with a series of fatty acids. They concluded that the strength of the ion-pair 
stability is the key factor in controlling the dissociation of the ion-pair when applied to the 
biological system.  
 
In addition to using excess spermine counter-ion to force to the drug to remain bound to the 
counter-ion, CDs could be used to stabilize this weak interaction. Many published studies 
have suggested that CDs can improve the stability of encapsulated guest molecules through 
host-guest complexation. The complexation provides insulation to the labile drug molecules 









The presence of active efflux mechanism is relevant to PTS activity as substrates for the PTS 
may be effluxed from the cells by P-gp transporters. It is known the activity of efflux pumps 
often limits the accumulation of a drug in cells (Gottesman & Pastan 2015; Hamilton et al. 
2001; Borges-Walmsley et al. 2003). The P-gp substrates can be varied in their chemical 
structures, from a small molecule such cimetidine (MW = 250 g mol-1) to a big molecule such 
as cyclosporin (MW = 1202 g mol-1). Drugs with poor membrane permeability may also 
undergo a substantial extrusion (Amin 2013). The protein responsible for these pumps 
actively extruding absorbed drugs out of the apical membrane resulting in a very limited 
amount of drug ultimately available to be absorbed in target organs. Of all, the P-gp protein 
encoded by MDR1 gene which belongs to the ATP-binding cassette (ABC) superfamily of 
proteins has been considered as one of the most significant transporters in humans (Aszalos 
2004; Kim 2002). Overexpression of P-gp transporters in cancer cells was found to form a 
strong link in resistance to many drugs used in chemotherapy (Peng et al. 2012).  
 
The aim of this chapter was to understand how forming a theophylline-spermine ion-pair 
influenced its absorption into the lung. The objectives of the chapter were (i) to assess the 
accumulation theophylline in A549 cells when dosing the drug as an ion-pair with spermine, 
(ii) to study the cell uptake of theophylline when cyclodextrin was added to the ion-pair 
formulation and (iii) to investigate whether the accumulation of theophylline was affected by 













Theophylline (THE) (anhydrous, > 99%), spermine (SP) (> 99%), beta-cyclodextrin (B-CD) 
(> 97%), 2-hydroxypropyl-beta-cyclodextrin (HP-B-CD), gamma-cyclodextrin (G-CD), 
valspodar (> 98%), elacridar (> 98%),  propylene glycol (PG, USP grade) and all reagents for 
cell culture (RPMI-1640 cell culture medium, fetal bovine serum (FBS), L-glutamine, 
penicillin-streptomycin, trypsin-EDTA 0.25%, phosphate buffered solution (PBS), Hank’s 
Balanced Salt Solution (HBSS), trypan blue and Triton TMX-100) were purchased from 
Sigma Aldrich, UK. 8-14C theophylline (0.1 mCi/mL, > 98%) was purchased from American 
Radiochemicals, USA. Human lung epithelial A549 cells were obtained from American Type 
Culture Collection (ATCC), USA and Optiphase “Safe” scintillation cocktail was purchased 
from Fisher Scientific International, UK. 
 
5.3 Methods 
5.3.1 Cell culture 
 
In the present study, the human lung epithelial (A549) cells were not used as a target site of 
theophylline but rather it was used as a robust model to assess the effects of PTS and P-gp 
transporters on the cellular accumulation of the drug ion-pair. These transporters have been 
well characterized in these cells.  The cells were used between passages 46-64. The cells 
were maintained in a 95 % humidified/ 5 % CO2 atmosphere at 37 oC. They were grown in 
75-cm2 flasks and cultured using RPMI-1640 cell culture medium supplemented with 10 % 








every 2/3 days. When the cells reached 90 % confluency (checked visually using a light 
microscope), they were sub-cultured at 1:3 split ratio using 0.25%trypsin/0.1% EDTA.  
 
5.3.2 In-vitro cell biocompatibility 
 
The cell biocompatibility of the individual compounds (THE, SP, B-CD, HP-B-CD, G-CD) 
and the mixtures with and without cyclodextrin (CD) (i.e., with CD: CD-THE-SP, without 
CD: THE-SP) was assessed by exposing the cells to the test solutions prepared at the desired 
concentrations. These concentrations once proven safe to the cells were later used in the 
accumulation studies of theophylline. The test solutions were prepared in two different 
vehicles, water and 70/30 (v/v) PG:water.  The pH of all test solutions was adjusted to 9.6 ± 
0.1 using 0.01 M NaOH/HCl. The toxicity of the test solutions was assayed using the 
standard MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide) test 
(Matilainen et al. 2008). Briefly, the cells were seeded into a 96-well plate at a density of 1.0 
x 104 cells/cm2. They were allowed to grow for 24 h at 37 oC in a 5 % CO2 atmospheric air 
incubator. After 24 h, the old medium was removed and each well was rinsed three times 
with pre-warmed PBS. Subsequently, 100 µL of pre-warmed HBSS was added to each well. 
An aliquot (100 uL) of test solutions was added to initiate the experiment and the cells were 
incubated for 1 h. Untreated cells, i.e, cells incubated with cell culture medium only were 
used as a negative control whilst cells treated with 1% Triton X solution were used as a 
positive control. After treatment, the cell media was discarded and replaced with 10% of        
5 mg/mL MTT in 100 µL of cell culture medium solution. This solution was incubated with 
the cells for 4 h. The cells were then lysed with 100 µL of lysis solution (10 % SDS in 








number of viable cells, was carried out using a multiwell plate reader (Spectramax 190) at 
570 nm (reference wavelength 690 nm). Relative cell viability was determined by dividing 
the optical density (OD) of treated wells over the OD of control. Experiments were repeated 
in triplicates (n=3 plates for each treated group) and the data were presented as mean + SD. 
 
5.3.3 Theophylline accumulation studies  
 
Cells were seeded onto a 12-well plate at a density of 2 x 105 cells/cm2. The culture medium 
was changed every other day until a confluent monolayer was established (approximately by 
4 days post seeding), as determined visually using a light microscope. To investigate 
theophylline uptake, the cell culture medium was removed and the cells were washed three 
times with pre-warmed PBS. The cells were then submerged in 0.5 mL pre-warmed HBSS 
for 30-min. The uptake studies of theophylline were initiated by the application of 0.5 mL 
test solutions, containing [14C]-theophylline. At 2, 5, 10 and 20-mins, the cell media was 
carefully aspirated and the cell layers were washed three times with ice-cold PBS. The cell 
layers were lysed by adding 1 mL of 1% Triton X solution for 45-mins at 37 0C. The activity 
associated with the cell layers was determined by scintillation counting following the 
addition of scintillation cocktail. The protein content of each monolayer was determined 
using the BCA assay reagent kit. The results were expressed as total accumulation of 
theophylline per microgram of protein. The experiments were performed at 37 and 4 0C. Each 










5.3.4 P-glycoprotein (P-gp) inhibition studies 
 
A similar protocol as the one described in 5.3.3 was employed for the P-gp inhibition studies 
except for before cells were exposed to the test solutions, they were pre-incubated with the 
appropriate inhibitors (5 µM of elacridar and 4 µM of valspodar) for 30-min. Both inhibitors 
were first dissolved in DMSO due to their low solubility in HBSS and further diluted to the 
desired concentrations using HBSS (the final vehicle composition contained <0.1% (v/v) of 
DMSO). The subsequent steps were identical as to the procedure as described in 5.3.3. 
 
5.3.5 Statistical analysis 
 
Data were presented as mean ± standard deviation (SD). Statistical significance was 
performed using paired student’s t-test (SigmaPlot13). A p < 0.05 was considered as 
statistical significant.  
 
 
5.4 Results and discussion 
5.4.1 MTT assay 
 
The MTT assay was performed to assess the A549 biocompatibility of the theophylline test 
solutions in two different vehicles, water and 70% PG-water. The application systems were 
pH adjusted to 9.6 to mimic the formulation pH, however it was appreciated that the cells of 
the lung would never be exposed to this kind of pH in-vivo. As a result, a system was used 
that mixed the pH 9.6 with the cell media. The optimum water (pH 9.6)-HBSS (pH 7.4) ratio 








significantly (Figure 5.1). This reduction was thought to be induced by the change in the 
overall pH of the accumulation medium as reported by Cutaia et al., (2005), who noted the 
effect of alkaline stress-induced apoptosis in human pulmonary artery endothelial cells. As a 
consequence, a 1:1 mixing ratio was chosen for the subsequent cell culture studies. The ratio 
1:1 refers to the application of 500 µL of test solution to the 500 µL submerged cells.  
 















pH 7.4 ± 0.05 pH 8.3 ± 0.22
pH 8.9 ± 0.18




Figure 5.1 Percentage of A549 cell viability after 1h incubation at 37 oC with different ratios 
(v/v) water (pH 9.6):Hank’s Balanced Salt Solution (HBSS), pH 7.4) assayed by MTT assay 
(n=3 + SEM). All pH values indicated the final pH of the water:HBSS mixture. *statistically 
significant (p<0.05) when compared to 100% cell viability (Student’s t-test). The data for pH 
8.9 ± 0.18 was highlighted to justify the application of 500 µL of test solution to the 500 µL 
submerged cells (1:1 test solution:HBSS ratio) in the subsequent experiments as above this 









The free theophylline (THE), spermine (SP), cyclodextrins (CD) as well as the complexes, 
i.e., THE-SP and CD-THE-SP in water and 70% PG-water pH adjusted to 9.6 and added to 
the HBSS submerged cells at the respective concentrations did not show any adverse effect 
up to a 1 h time-point (Figure 5.2). Note in the subsequent accumulation studies, it was the 
intention that the cells would only be incubated with the test solutions for 20 min. The 
biocompatibility data recorded in this study aligned with previous work. For example, 
Matilainen et al., (2009) demonstrated that low concentrations of the parent (α-, β- and γ-CD) 
and modified CDs (hydroxypropyl-α and –β-CDs and randomly methylated-β-CD) (< 1 mM) 
was safe for local pulmonary application when tested in Calu-3 cells. However, at higher 
concentrations (> 2 mM), different cytotoxic effects were seen depending on the CD used. Of 
these three parent CDs, γ-CD was found to be the safest. This was thought due to its high 
solubility that limits its interaction with the cell membranes. Whilst between the modified 
types of CDs, they found that the methylated CD was more toxic compared to the 
hydroxypropyl- α and –β-CDs. This was most likely due to the ability of the methylated CD 
to interact and permeate through the cell membrane. The toxicity of CDs in cells was 
normally associated with the hemolytic activity and cholesterol-solubilizing ability of CDs 
(Boulmedarat et al. 2005; Ulloth et al. 2007; Kiss et al. 2010). In case of spermine, it can be 
toxic to cells when presented at 30 mM (Sharmin et al. 2001). This toxic effect was 
associated with the presence of amine oxidase enzyme in the culture medium. This enzyme 
degraded spermine into amino aldehydes, H2O2 and ammonia. These toxic products are able 
to induce stress-activated signal transduction pathways, leading to cell death, necrosis or 
apoptosis, in several cultured tumour cell lines (Averill-Bates et al. 2008). However, it should 
be noted that the presence of serum amine oxidase is species-specific, and the potential 



































































































































































































Figure 5.2 The percentage of viable A549 cells after 1h incubation at 37 oC with (i) (0.14, 
2.78, 27.8 µM) free theophylline, (ii) free spermine (55.6 µM), (iii) free cyclodextrins (2.78 
µM), (iv) theophylline-spermine ion-pair (2.78:55.6 µM; 1:20 molar ratio) and (v) 
theophylline-spermine ion-pair complexed with cyclodextrins (2.78:2.78:55.6 µM; 1:1:20 
molar ratio) to the HBSS-submerged cells assayed by MTT test. All solutions were prepared 
in water (graph A) and 70/30 (v/v) propylene glycol (PG)/water (graph B) pH adjusted to 9.6. 








However, a study by Dolby et al., (1981) showed that the addition of 5 mM of theophylline to 
Hela-S3-cells caused a negative effect on the DNA synthesis. Murnane et al., (1981) showed 
that the lethal effect of caffeine which belongs the same family of methylxanthines as 
theophylline at high concentrations (7.5 and 10 mM) was due to its ability to interrupt the 
DNA synthesis when studied in human HT-29 cells. 
 
5.4.2 Drug uptake studies 
 
Theophylline displayed a concentration-dependent accumulation in-vitro when tested within 
the range of  0.14 – 27.8 µM (Figure 5.3). 
 













































Figure 5.3 Total accumulation of theophylline in human lung epithelial A549 cells (nmoles 
per µg of protein) at 2-min, 37 °C after the application of theophylline solutions (0.14, 2.78, 










It was anticipated that theophylline, due to its small molecular size (MW = 180.16 g moL-1), 
could passively permeate through the cell membrane (Lipinski et al. 1997). This has been 
previously reported by Bellemann and Scholz (1974) when assessing the drug uptake in the 
guinea-pig heart. The low percentage of drug accumulation (ca. 0.2%) which was in line with 
the finding reported by Beanouda et al., (2018) indicated a very weak affinity of theophylline 
to the cells. The limited cell uptake of theophylline could be due to the molecules poor 
lipophilicity. The log D values of theophylline were previously determined in Chapter 2 of 
this thesis using the octanol/water partitioning experiments: log D7.4 = -0.025 ± 0.008, log 
D9.6 = -0.186 ± 0.015). To support this hypothesis, Arakawa and Kitazawa (1987) showed 
that the pulmonary absorption of theophylline was massively influenced by it lipophilicity 
when tested in rats. This was evidenced by a significant 11 % reduction of theophylline 
absorption when administered in a solution at pH 9.4 compared to its absorption at pH 7.4. 
The pKa of theophylline is 8.6. At pH 9.4, theophylline was primarily existed ionized whilst 
at pH 7.4, the drug was presented uncharged in the solution which allowed better penetration 
of theophylline across the cell layers.  
 
The total accumulation of theophylline in the lung epithelial cells did not increase as a 
function of time when tested up to 20-min, at 37 oC (Figure 5.4A). This suggested that 
theophylline quickly exited the cells once absorbed. A similar observation has been reported 
previously (Arakawa & Kitazawa 1987). In this study, ca. 90% of the theophylline was 
transferred into circulation following 1 min of pulmonary administration. Similarly, a similar 
observation was reported by Belleman and Scholz (1974) reported that theophylline uptake 
was rapid (>95% of drug absorption within 3 min), but after 5 min, >95% of the drug was 
washed out from the cells. In the current work it was thought that the poor accumulation of 








accumulation experiment was repeated at 4 oC. It is known that the membrane transport at 4 
oC suppresses the activity of active efflux tremendously due the depletion of the ATP 
production (Bratic & Trifunovic 2010). Interestingly, at 4 oC, the total accumulation of the 
drug increased as a function of time (Figure 5.4B). The total accumulation of theophylline 
was 2.6-fold higher after 20-min at 4 oC compared to its accumulation at 37 oC after 20 min 
incubation. This suggested that the poor accumulation of theophylline could be attributed to 
active efflux. This effect was further investigated. 



























































































Figure 5.4 Total accumulation of theophylline in human lung epithelial A549 cells (nmoles 
per µg of protein) at 37 °C (graph A), 37 vs 4 °C (graph B) following the application of 2.78 
µM theophylline to the HBSS-submerged cells at 2, 5, 10 and 20 minutes. All solutions were 
prepared in water at pH 9.6 and mixed with HBSS on the cell surface (n=3 + SD). 
*statistically significant (p<0.05) when compared the total accumulation of theophylline 








5.4.3 P-gp inhibition studies 
 
A functionalized P-gp activity in A549 cells have been reported before (Xu et al. 2014; 
Hamilton et al. 2001). In this study, when the cells monolayer was pre-incubated with the 
specific P-gp inhibitors, elacridar and valspodar for 30-min, a significant 2-fold increment of 
total theophylline accumulation was achieved up to 20-min compared to the total 
accumulation when dosing the drug to the cells in the absence of the P-gp inhibitors (Figure 
5.5). Both elacridar and valspodar are listed in the FDA list (last updated 26/9/2016) as 
specific inhibitor for P-gp transporter.  
 













































Theophylline + 5 µM elacridar
Theophylline + 4 µM valspodar
 
 
Figure 5.5 Effect of specific P-gp inhibitors (5 µM of elacridar and 4 µM of valspodar) on 
the total accumulation of theophylline in A549 cells at 37 oC at 2,5, 10 and 20-min. The 
figure shows the total accumulation of theophylline (nmoles per µg of protein) following the 
application of 2.78 µM of theophylline prepared in water pH 9.6 to HBSS submerged cells 
after 30 mins incubation with the inhibitors. Cells treated with theophylline without pre-








5.4.4 Effect of polyamine ion-pairing on theophylline cell uptake 
 
A significant increase (p<0.05) in theophylline accumulation in A549 cells was observed at 
t=2-min and 5-min when mixed with excess spermine counter-ion compared to the uptake of 
the drug alone (Figure 5.6). This relationship between the spermine concentration and its 
effects on the theophylline uptake was attributed to the ion-pairing effect where the presence 
of excess spermine in the medium forced the drug to bind to the counter-ion. However, over 
time, the percentage increase of drug uptake started to decrease significantly, which was 
thought to be induced by the dissociation of the ion-pair (as predicted in Chapter 4). The 
increase of theophylline ion-pair uptake by A549 cells was thought to be a consequence of 
the active PTS. Alternative mechanisms such as the ion-pair increasing cell uptake due to 
enhanced passive transport was unlikely to occur. This was due to a significant increase of 
theophylline polarity when mixed with spermine as mentioned previously. A similar trend of 
theophylline-spermine ion-pair (1:20 ratio) and free theophylline was observed at 4 oC 
(Figure 5.7). This again supported the idea that the theophylline-spermine ion-pair cell 


































































Figure 5.6 Increase percentage of the total accumulation of theophylline (nmoles per µg of 
protein) in lung epithelial A549 cells at 37 °C following the application of 2.78 µM free 
theophylline and theophylline mixed with spermine at different molar ratios (1:5, 1:10 and 
1:20) to HBSS-submerged cells at 2, 5, 10 and 20-mins. All solutions were prepared in water 
pH adjusted to 9.6 (n=3 + SD). Increase % of accumulated theophylline was calculated 
against the total accumulation of free theophylline. *statistically significant (p<0.05) when 
compared to the total accumulation of the free theophylline (Student’s t-test). 
 
 
Unfortunately, to-date, there is not a highly specific polyamine transporter inhibitor to test the 
hypothesis using inhibition studies. Furthermore, the concentration dependence, and hence 
saturation of the uptake process, could not be observed in the presence of the P-gp efflux. An 
additional complicating factor to the studies was that the spermine concentration (SP at 55.6 
µM) applied to the cells, which exceeded the PTS Km (at 0.5 µM) recorded for the 
spermidine uptake (Cullis et al. 1999) and hence the free unbound spermine, which is needed 























































Figure 5.7 Total accumulation of theophylline (nmoles per µg of protein) in lung epithelial 
A549 cells at 4 °C following the application of free theophylline (2.78 µM) and theophylline 
mixed with spermine (2.78:55.6 µM; 1:20 molar ratio) to HBSS-submerged cells at 2, 5, 10 
and 20-min. All solutions were prepared in water pH adjusted to 9.6 (n=3 + SD).  
 
 
The possibility of other active transporters increasing the uptake of the ion-pair was 
considered to be unlikely. The OCT transporter is known to sequester polyamines, but recent 
studies have shown that this active transport mechanism is 30-fold less efficient at moving 
amines into cells compared to the PTS (Sala-Rabanal, Li, et al. 2013). Thus, the conclusion 
that the PTS facilitated the theophylline ion-pair uptake into the A549 cells despite the 
potential complexities of how it achieved this was considered reasonable. 
 
To further assess the effect of ion-pairing on the drug uptake into the cells, the theophylline-
spermine (1:20) was prepared at pH 7.4 and 9.6 (Figure 5.8). The final pH of the 
accumulation medium when 0.5 mL of test solution (pH 9.6) was mixed with 0.5 mL HBSS 








the mixture was prepared at pH 9.6 compared at pH 7.4. Using pKa of theophylline (8.6), 
HySS predicted that ca. 30% of theophylline is deprotonated at pH 8.3 compared to only ca. 
7% at pH 7.4 indicating a greater potential of ion-pairing effect when dosing the ion-pair 
formulation at pH 9.6 to the cells.  
 
 

















































Figure 5.8 Total accumulation of theophylline (nmoles per µg of protein) in lung epithelial 
A549 cells at 37 °C following the application of theophylline mixed with spermine (2.78:55.6 
µM; 1:20 molar ratio) to HBSS-submerged cells at 2, 5, 10 and 20-min. All solutions were 
prepared in water pH 7.4 or 9.6 (n=3 + SD).  
 
 
In the previous chapter, theophylline was found to exhibit greater affinity towards spermine 
when mixed in 70% PG-D2O mixed solvent. However, no significant enhancement of drug 
uptake was seen when the theophylline-spermine mixture was prepared in 70% PG-H2O and 
exposed to the cells compared when the formulation was made in H2O (Figure 5.9). This 
























































Figure 5.9 Total accumulation of theophylline (nmoles per µg of protein) in human lung 
epithelial A549 cells at 37 °C following the application of theophylline-spermine ion-pair 
(THE-SP) (2.78:55.6 µM; 1:20 molar ratio) prepared in water and 70/30 (v/v) propylene 




The effect of vehicle viscosity on drug absorption has been studied before. Levy and Jusko 
(1964) assessed the absorption rate of ethanol and salicylic acid from the stomach of rats 
when administered in an aqueous solution containing increasing methylcellulose, which gave 
a viscosity range from 1 to 500 cps. In this study, the osmotic pressure was kept the same. 
The results showed an inverse correlation between viscosity and the molecules absorption 
rate. Levy and Jusko suggested that the decrease in drug absorption rate in a more viscous 
solution was due to the movement retardation of the molecules to the absorption site hence 
slowed the gastrointestinal transit. In another study by Furubayashi et al., (2007), they 
concluded that dosing solution with higher viscosity decreased drug i.e., acyclovir absorption 








in-vitro Caco-2 system using dextran (DEX) as a dosing solution (Moderate viscosity = 20% 
DEX, High viscosity = 40% DEX).  
 
A sustained retention of theophylline over time in the cells was achieved when dosing the 
ion-pair as complexed with cyclodextrins to the cells (Figure 5.10). This was seen up to 20-
min. The ion-pair complexed with BCD exhibited a higher percentage of drug uptake 
compared when complexed with HPBCD and GCD. This could be associated to the higher 
binding capacity of BCD toward the ion-pair than HPBCD and GCD (as shown in Chapter 
3). This suggested that the complexes formed between cyclodextrins and the ion-pair 
stabilized the weak association of the ion-pair resulted in a longer retention of the drug in the 
cells. The hydrophobic cavity of CDs was thought to provide a physical protection of the 
encapsulated fraction of the ion-pair from the extracellular medium, which resulted in 
improved of stability. The possible hydrogen bonding between the ion-pair with the hydroxyl 
group on the outer rim of CD enhanced the complex formation hence improved the overall 






























































Figure 5.10 Percentage of increase of the total accumulated theophylline in human lung 
epithelial A549 cells at 37 °C following the application of (i) theophylline-spermine ion-pair 
(THE-SP) (2.78:55.6 µM; 1:20 molar ratio) and (ii) THE-SP complexed with gamma-
cyclodextrin (GCD:THE:SP, 2.78:2.78:55.6 µM; 1:1:20 molar ratio), 2-hydroxypropyl-beta-
cyclodextrin (HPBCD:THE:SP, 2.78:2.78:55.6 µM; 1:1:20 molar ratio) and beta-cyclodextrin 
(BCD:THE:SP, 2.78:2.78:55.6 µM; 1:1:20 molar ratio) to HBSS-submerged cells at 2, 5, 10 
and 20-min. Increase % of accumulated theophylline was calculated against the total 
accumulation of free theophylline. All solutions were prepared in water pH adjusted to 9.6 


















The free theophylline, spermine, cyclodextrin and their complexes were found to be well-
tolerated to the HBSS submerged A549 cells when tested at the respective concentrations 
using a MTT assay.  An improved accumulation of theophylline in A549 cells that was most 
likely to be mediated by PTS was achieved when dosing the drug as ion-pairing with excess 
spermine to the cells. Interestingly, a more sustained retention of the drug in the cells was 
seen when dosing the drug as ion-pair complexed with CDs suggested the ability of CDs to 
control the stability of the ion-pair. It was also found that the short retention time of 
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6.1 General discussion 
 
The field of drug delivery has grown tremendously over the last few decades. Numerous new 
materials have been synthesized to be used in drug delivery and different approaches have 
been designed and tested with the ultimate aim to improve the treatment efficacy. One focus 
in this field is the development of a delivery system that can deliver bioactive agents 
specifically to target sites whilst minimizing harmful side-effects (Tian et al. 2017; Bashari et 
al. 2017; Papa et al. 2017). In this thesis, the polyamine ion-pairing approach was explored 
for lung-targeting delivery using theophylline as a model drug. It was hoped such targeting 
system could improve the nonspecific tissue distribution of theophylline when administered 
intravenously for anti-asthmatic treatment. The structure-activity studies have established that 
good PTS substrates require two or more N-containing moieties that are protonated at 
physiological pH. As very few therapeutic agents that require delivery into the lungs display 
these structural characteristics, the attempt to use a number of polyamine drug analogues and 
covalent polyamine drug conjugates to manipulate the PTS to target delivery to the lungs 
have had limited success because combining the molecular features required for effective 
active PTS transport and pharmacological action in a single molecule is problematic (Wang 
et al., 2003; Tomasi et al., 2010).  
 
Secondary to that, since ion-pairs associations are temporary, they will almost certainly revert 
back into their parent ions and eliminated individually when enter the biological systems (W. 
Wang et al. 2017; Zhao et al. 2017b). Hence, forming a drug ion-pair not only offers 
simplicity in terms of sample preparation, but it also allows the active molecule to be 
presented in its original form upon dissociation hence bypassing any pharmacological and 








reasonable that drug ion-pairs that are formed through multiple hydrogen bonds could stay 
associated during the absorption process and this hypothesis has been supported by previous 
studies that show ion-pair formation influences absorption via the skin, GI tract and 
respiratory system. The spectroscopy data gathered for theophylline-amine mixtures 
suggested that ion-pairs were formed between theophylline and all of the counter-ions tested 
in the aqueous (Figures 2.3 and 2.4, Chapter 2), EtOH and PG-water co-solvents (Figures 4.2 
and 4.3, Chapter 4) vehicles at pH 9.6. The differences in ion-pair affinities across the 
homologous series of amines were thought to be due to the differences in the hydrogen 
bonding capacity of amine counter-ions with the theophylline. The HPLC affinity 
coefficients were identical in rank order to the FT-IR measurements, but in all cases the 
absolute value was approximately 1 log unit higher. The HPLC studies analysed theophylline 
samples that were at least 1 order of magnitude lower in concentration (this value is probably 
> 1 order of magnitude due to dilution upon the HPLC column). As theophylline is prone to 
dimerization, it could be that at higher drug concentrations, when the theophylline is more 
likely to dimerise its affinity with the amine counter-ions is lower. Although the HPLC 
concentrations were closer to the cell uptake concentrations and more like those found in 
vivo, the FT-IR values were used in the calculations of percentage ion-pair formation in the 
cell culture work as this was more conservative and less likely to falsely inflate the impact of 
the results.  
 
 
The effects of the co-solvent on the ion-pair association was only demonstrated using the 
strongest theophylline-spermine ion-pair. With this test system, the addition of an organic 
component to the solvent (PG and EtOH) showed a minimal impact on the ion-pair 








ion-pair interactions were most likely due to the weakening of the water’s supramolecular 
structure in the organic mixed solvent systems (Benaouda et al. 2012). The ability to change 
the association strength of the complex, through modification of the solvent in which it was 
dissolved, provided a degree of flexibility in this drug targeting approach, as presumably a 
greater association of the complex would lead to slower release of the parent drug from the 
ion-pair upon administration, however the in-vitro dissociation experiments did provide 
support to this notion (Figures 4.6 and 4.7, Chapter 4). This may have been a consequence of 
the lack of sensitivity in the dissociation assay or it could have been that the small differences 
in association constants having little practical significance.  
  
Drug ion-pair dissociation is driven by fluctuations in pH and the dilution effects experienced 
during the drug absorption process, but it is problematic to directly study this process using 
traditional analytical techniques during the process of drug absorption. One of the issues 
faced when trying to understand ion-pair cell uptake is defining the concentrations of the ion-
pairs that are presented to the absorptive barrier. Simply adding an equal molar equivalent 
ratio of drug and counterion does not generate 100% of the 1:1 ion-paired system due to their 
relatively weak association strength. Previous work has measured the association constant, 
the relative concentrations of the parent drug and counterion and the pH to calculate the 
proportion of ion-paired drugs that were presented to cells in transport studies. From this 
work, it was discovered that for most ion-pairs to achieve a high degree of ion-pair formation 
an excess of counter-ion was required (Patel et al. 2016). A second issue faced when 
attempting to understand the ability of drug ion-pairs to influence absorption is the inability 
to predict or experimentally measure ion-pair dissociation during absorption. Currently the 
best way to determine if the ion-pair does stay intact during the cell uptake is to characterise 








changes in drug, counter-ion and competing ionised molecule presence, which can confound 
the sound interpretation of some experiments, it is possible using tightly controlled functional 
studies to investigate the effects of ion-pairs on absorption in-vitro, ex-vivo and in-vivo. 
 
Mixing theophylline with increasing levels of the amine counter-ions diminished the drug’s 
lipophilicity and significantly increased its aqueous solubility (Figure 2.9, Chapter 2). This 
effect was opposite to the traditional notion that ion-pair formation always results in an 
increase in lipophilicity. The results demonstrated that ion-pair properties are a function of 
both the drug and counter-ion properties and when these two elements are held together in a 
complex it can be more hydrophilic compared to the parent compound. The effects of ion-
pair formation on solubility were more apparent at pH 9.6 compared to pH 7.4 presumable 
due to the greater proportion of ion-pairs formed at the more alkaline pH due to the 
theophylline’s pKa. However, that fact that the significant effects was observed at 
physiological conditions meant that the ion-pairing of the drug was still consequential even 
when only a small proportion of it was ionised. 
 
 
The uptake of theophylline into the lung epithelia cells was surprisingly low for a therapeutic 
agent that acts in the lung tissue (ca. 0.035 nmoles per g of tissue) (Figure 5.3, Chapter 5). 
However, previous theophylline bio-distribution studies support this low uptake. Although 
the A549 cells showed a dose dependant uptake at 2 min they failed to accumulate the drug 
over a 20-min period. It was unlikely that theophylline transport into the cells had reached its 
passive transport equilibration point after only 2 min given that only approximately 0.2 % of 
the drug have moved into the cells after 2 min and that the dose dependant uptake showed 








equilibration point in cell uptake was achieved as a result of the uptake and efflux processes 
finding equipoise. The increased of drug uptake when ion-paired with spermine was most 
likely to be mediated by the polyamine transporter system (PTS) because the more 
hydrophilic nature of the ion-pair compared to the parent drug was not likely to enhance 
passive cell drug accumulation (Figure 5.6, Chapter 5). The structure-activity studies have 
established that good PTS substrates require two or more N-containing moieties that are 
protonated at physiological pH. As very few therapeutic agents that require delivery into the 
lungs display these structural characteristics, a number of polyamine drug analogues and 
covalent polyamine drug conjugates have been developed in an attempt to use the PTS to 
target delivery to the lungs. However, these strategies have had limited success because 
combining the molecular features required for effective active PTS transport and 
pharmacological action in a single molecule is problematic. Since the specific gene 
responsible to modulate the PTS in animal cells is not known, the confirmation molecular 
biology techniques could not be used to confirm this PTS mediated theophylline-spermine 
ion-pair into cells. Functional studies, which increased the ion-pair, reduced the transport 
temperature all pointed to the PTS are the mechanism of active uptake, but it is possible that 
another transporter such as the OCT transporter could have been involved in this process 
(Sala-Rabanal et al. 2013). Apart from that, the increase in the cell uptake of theophylline 
when presented as ion-pair to the cells could also be facilitated by an advanced endocytosis 
process.  
 
Cell pre-incubation with the P-gp inhibitors elacridar and valspodar suggested active drug 
efflux (Figure 5.5, Chapter 5). In addition to P-gp both BCRP and MRP2 could be inhibited 
by elacridar (BCRP) and valspodar (MRP2) , but unlike P-gp there is not studies confirming 








literature, theophylline has not been reported to be a P-gp substrate. Wang et al. (2005), using 
an unsupervised machine learning approach based on the Kohonen self-organizing maps 
(SOM) (average accuracy of 82.3%) which incorporated a predefined set of physicochemical 
descriptors encoding the key molecular properties suggested that a theophylline-like 
molecule i.e., caffeine as an unfit molecule to be a P-gp substrate. However, until the 
gathering of more data it seemed reasonable to suggest that the ca. 2-fold increase of the total 
accumulated theophylline in the pre-incubated cells with the inhibitors owas a consequence 
of efflux and this could have been mediated by the P-gp as both elacridar and valspodar are 
both known P-gp inhibitors.  
 
A sustained retention of theophylline over time in the cells was achieved when dosing the 
ion-pair as a cyclodextrin complex to the cells (Figure 5.10, Chapter 5). Our findings 
suggested that the hydrophobic cavity of cyclodextrin could provide a physical protection of 
the encapsulated lipophilic part of the ion-pair which resulted in a relatively stronger 
association of the theophylline-spermine ion-pair to withstand the corrosive environment at 
the extracellular level. Apparently more work is required to understand the relationship 
between drug ion-pair association strength, physical stability and their ability to influence 
absorption in-vivo. Further in-vivo work is obviously necessary to assess the influence of 
ion-pair formation on in-vivo bio-distribution which would help not only to understand the 
significance of the physical stability of the ion-pair on its whole body distribution but also aid 











6.2 Future studies  
 
In this present study, in-vitro studies suggested that ion-pairing spermine with theophylline 
formulated using cyclodextrins improved the cell uptake of the drug into the lung cells. In 
order to prove that this strategy can improve theophylline lung-targeting delivery, in-vivo 
studies need to be carried out. The theophylline test formulations can be introduced to the 
animals using tail injection method. After 5-min and 60-min time points, the major organs 
(brain, liver, spleen, kidney, heart) should be harvested to trace the amount of theophylline in 
the respective tissue. The amount of theophylline in the blood should also be examined. The 
biodistribution studies should be performed with and without the presence of the polyamine 
and cyclodextrin to assess the impact of these molecules on the biological behavior of the 
drug.  
 
The current work suggests that PTS will not only extract polyamines from the circulation into 
the lung, but can also transport therapeutic agents ion-paired to polyamines, in this case 
theophylline. This mechanism could also be utilized for other drugs that can ion-pair with 
polyamines. Since it is known that cancer cells overexpressed PTS, ion-pairing polyamine 
with an anti-cancer agent could provide a new means to improve the anti-cancer treatment. 
One agent which could benefit from this is 5-fluorouracil (5-Fu) which is currently used in 
the treatment of cancers. The drug has a pKa of 8 which means that it is ionizable at 
physiological pH and hence has the potential to form an ion-pair with a polyamine. 5-Fu-
based chemotherapy has been shown to improve overall and disease-free survival of patients 
but chemoresistance of 5-Fu is one of the major challenges (Zhao et al. 2014). 
Physicochemical characterization (binding, log D and solubility studies) of 5-Fu complexed 








between these molecules occur in addition to in-vitro and in-vivo studies. Apart from using 
the known existence polyamine e.g., spermine to form ion-pairing with drugs for targeting 
delivery, future studies can also explore the use of novel polyamine analog to form drug ion-
pair as this could also provide a new strategy for anti-cancer treatments since a study by Alm 
et al., (2000) demonstrated significant disturbances in polyamine metabolism caused by 
treatment with the spermine analog DENSPM when tested in Chinese hamster ovary cells. 
However, since the instability of this association can cause major setback of this approach, 
future studies also need to focus on finding a strategy to overcome this issue. This can be 
done by evaluating different strategies (e.g., using liposomes formulated using cylcodextrins 
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